<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
<journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="publisher-id">09-PLCB-RA-0473R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1000533</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Infectious Diseases/HIV Infection and AIDS</subject><subject>Mathematics</subject></subj-group></article-categories><title-group><article-title>Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy</article-title><alt-title alt-title-type="running-head">Latently Infected Cell Activation</alt-title></title-group><contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rong</surname><given-names>Libin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Perelson</surname><given-names>Alan S.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group><aff id="aff1">          <addr-line>Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America</addr-line>       </aff><contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Antia</surname><given-names>Rustom</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group><aff id="edit1">Emory University, United States of America</aff><author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">asp@lanl.gov</email></corresp>
<fn fn-type="con"><p>Conceived and designed the experiments: LR ASP. Performed the experiments: LR. Analyzed the data: LR. Contributed reagents/materials/analysis tools: LR. Wrote the paper: LR ASP.</p></fn>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="collection"><month>10</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2009</year></pub-date><volume>5</volume><issue>10</issue><elocation-id>e1000533</elocation-id><history>
<date date-type="received"><day>30</day><month>4</month><year>2009</year></date>
<date date-type="accepted"><day>15</day><month>9</month><year>2009</year></date>
</history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2009</copyright-year><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</license-p></license></permissions><abstract>
<p>Although potent combination therapy is usually able to suppress plasma viral loads in HIV-1 patients to below the detection limit of conventional clinical assays, a low level of viremia frequently can be detected in plasma by more sensitive assays. Additionally, many patients experience transient episodes of viremia above the detection limit, termed viral blips, even after being on highly suppressive therapy for many years. An obstacle to viral eradication is the persistence of a latent reservoir for HIV-1 in resting memory <italic>CD</italic>4<sup>+</sup> T cells. The mechanisms underlying low viral load persistence, slow decay of the latent reservoir, and intermittent viral blips are not fully characterized. The quantitative contributions of residual viral replication to viral and the latent reservoir persistence remain unclear. In this paper, we probe these issues by developing a mathematical model that considers latently infected cell activation in response to stochastic antigenic stimulation. We demonstrate that programmed expansion and contraction of latently infected cells upon immune activation can generate both low-level persistent viremia and intermittent viral blips. Also, a small fraction of activated T cells revert to latency, providing a potential to replenish the latent reservoir. By this means, occasional activation of latently infected cells can explain the variable decay characteristics of the latent reservoir observed in different clinical studies. Finally, we propose a phenomenological model that includes a logistic term representing homeostatic proliferation of latently infected cells. The model is simple but can robustly generate the multiphasic viral decline seen after initiation of therapy, as well as low-level persistent viremia and intermittent HIV-1 blips. Using these models, we provide a quantitative and integrated prospective into the long-term dynamics of HIV-1 and the latent reservoir in the setting of potent antiretroviral therapy.</p>
</abstract><abstract abstract-type="summary"><title>Author Summary</title>
<p>Current combination therapy can suppress viral loads in HIV-1-infected individuals to below the detection limit of standard commercial assays. However, it cannot eradicate the virus from patients. HIV-1 can generally be identified in resting memory <italic>CD</italic>4<sup>+</sup> T cells and persists in patients on potent treatment for a long time. These latently infected cells decay slowly, but can produce new virions when activated by relevant antigens. Many patients experience transient episodes of viremia, or blips, even though they have “undetectable” plasma viral loads for many years. Here, we develop a new mathematical model describing latently infected cell activation upon random antigenic stimulation. Using the model, we show that programmed expansion and contraction of latently infected cells upon activation can generate both low viral load persistence and viral blips. Occasional replenishment of the latent reservoir may explain the different decay kinetics of the reservoir observed in clinical practice. We also show that a model with homeostatic proliferation of latently infected cells can explain persistence of low-level virus, stability of the latent reservoir, and emergence of viral blips. These results provide novel insights into the long-term virus dynamics and could have implications for the treatment of HIV-1 infection.</p>
</abstract><funding-group><funding-statement>Portions of this work were done under the auspices of the US Department of Energy (DOE) under contract DE-AC52-06NA25396. This work was supported by NIH grants AI28433 and RR06555. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="18"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Following initiation of highly active antiretroviral therapy (HAART) the plasma viral load declines with a rapid first phase, followed by a slower second phase (<xref ref-type="fig" rid="pcbi-1000533-g001">Figure 1</xref>, see reviews in <xref ref-type="bibr" rid="pcbi.1000533-Finzi1">[1]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Rong1">[3]</xref>). After several months of treatment, most patients attain a level of plasma HIV-1 RNA below the detection limit (e.g., 50 copies/mL) of current standard assays <xref ref-type="bibr" rid="pcbi.1000533-Perelson1">[4]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Hammer1">[6]</xref>. However, this does not imply that viral replication has been completely suppressed by therapy. On the contrary, even in patients with “undetectable” plasma viral loads for many years, a low level of virus can be detected in plasma by supersensitive assays <xref ref-type="bibr" rid="pcbi.1000533-Dornadula1">[7]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Palmer2">[9]</xref>. This phase with HIV-1 RNA below 50 copies/mL has been referred to as the third phase of viral decline after treatment <xref ref-type="bibr" rid="pcbi.1000533-Finzi1">[1]</xref> (<xref ref-type="fig" rid="pcbi-1000533-g001">Figure 1</xref>), although whether virus declines or persists at a constant level is still unresolved <xref ref-type="bibr" rid="pcbi.1000533-Palmer2">[9]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-DiMascio1">[10]</xref>. The factors influencing this low-level viral persistence and their relative contributions have not been fully elucidated. It is possible that current HAART regimens are not completely suppressive and HIV-1 continues to replicate, particularly in some drug sanctuary sites such as the brain and testes, where drugs have poor penetration (see <xref ref-type="bibr" rid="pcbi.1000533-Gunthard1">[11]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Smith1">[12]</xref> and reviews in <xref ref-type="bibr" rid="pcbi.1000533-Blankson1">[13]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Schrager1">[14]</xref>). A second explanation is that HIV-1 establishes a state of latent infection in resting memory <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e001" xlink:type="simple"/></inline-formula> T cells <xref ref-type="bibr" rid="pcbi.1000533-Chun1">[15]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Chun2">[16]</xref>, and virus is released when these cells encounter their relevant antigens and are reactivated <xref ref-type="bibr" rid="pcbi.1000533-Chun3">[17]</xref>. The latent reservoir persists in patients on HAART <xref ref-type="bibr" rid="pcbi.1000533-Chun4">[18]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Wong1">[20]</xref> and decays slowly, with the estimated half-life up to 44 months <xref ref-type="bibr" rid="pcbi.1000533-Finzi3">[21]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Siliciano1">[22]</xref>. It is more likely that both factors contribute to viral persistence. The latent reservoir releases virus that fuels ongoing viral replication, and ongoing viral replication replenishes the latent reservoir. We still lack a quantitative understanding of the relative contributions from residual ongoing viral replication and latent cell activation to the observed sustained low-level viremia.</p>
<fig id="pcbi-1000533-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g001</object-id><label>Figure 1</label><caption>
<title>Multiphasic viral decline after potent treatment.</title>
<p>After initiation of HAART, the plasma viral load undergoes a multiphasic decay and declines to below the detection limit (e.g., 50 RNA copies/mL) of standard assays after several months. A low level of viremia below 50 copies/mL may persist in patients for many years despite apparently effective antiretroviral treatment. Intermittent viral blips with transient HIV-1 RNA above the limit of detection are usually observed in well-suppressed patients.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g001" xlink:type="simple"/></fig>
<p>Another line of evidence for HIV-1 persistence is the observation of transient episodes of viremia (“blips”) above the detection limit in patients on HAART (<xref ref-type="fig" rid="pcbi-1000533-g001">Figure 1</xref>) <xref ref-type="bibr" rid="pcbi.1000533-Dornadula1">[7]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>. Because viral blips are relatively rare events, their occurrence time, frequency, duration and amplitude are not well known. Di Mascio et al. <xref ref-type="bibr" rid="pcbi.1000533-DiMascio2">[24]</xref> studied viral load time series with samples obtained approximately one month apart from 123 patients, and found that the mean blip frequency was <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e002" xlink:type="simple"/></inline-formula>, and the mean blip amplitude was <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e003" xlink:type="simple"/></inline-formula> RNA copies/mL. They also suggested that a viral blip was not an isolated event but rather an extended transient episode of viremia with a duration of approximately 3 weeks <xref ref-type="bibr" rid="pcbi.1000533-DiMascio3">[25]</xref>. In another study, Nettles et al. <xref ref-type="bibr" rid="pcbi.1000533-Nettles1">[26]</xref> examined the dynamics of blips with more intensive sampling over a shorter period in a cohort of 10 patients. They found that blips were brief with a mean duration of less than 3 days and had a mean amplitude of 79 copies/mL. Moreover, viral blips were not concordant on independent testing, indicating that random biological or statistical variation around a mean viral load less than 50 copies/mL might be responsible for the aberrant viral load measurements <xref ref-type="bibr" rid="pcbi.1000533-Nettles1">[26]</xref>. The observations by these studies may represent different phenomena, with Nettles et al. <xref ref-type="bibr" rid="pcbi.1000533-Nettles1">[26]</xref> observing the effects of assay variation and Di Mascio et al. <xref ref-type="bibr" rid="pcbi.1000533-DiMascio2">[24]</xref> observing higher amplitude blips generated by occasional immune activation events <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>.</p>
<p>The management of HIV-1 infection requires a further understanding of the mechanisms underlying low viral load persistence, stability of the latent reservoir, and occurrence of intermittent viral blips, as well as the relationships between them. We approach this through mathematical modeling. Many models, as surveyed in <xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref>, are not capable of realistically accounting for viral load persistence since the presence of low-level replication is extremely sensitive to small changes of drug efficacy. Studies of the dynamics of the latent reservoir and viral blips are also difficult because latently infected cells are very rare <xref ref-type="bibr" rid="pcbi.1000533-Chun1">[15]</xref> and blips appear to emerge randomly <xref ref-type="bibr" rid="pcbi.1000533-DiMascio2">[24]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Nettles1">[26]</xref>. Considering the heterogeneity of the pool of latently infected cells, a simple model was developed to study the decay characteristics of the latent reservoir <xref ref-type="bibr" rid="pcbi.1000533-Muller1">[29]</xref>. Kim and Perelson <xref ref-type="bibr" rid="pcbi.1000533-Kim1">[30]</xref> extended the model and showed that the latent reservoir persistence could be explained by bystander proliferation of latently infected cells. The relationship between low-level viral replication and the decay of the latent reservoir was examined in a recent study by Sedaghat et al. <xref ref-type="bibr" rid="pcbi.1000533-Sedaghat1">[31]</xref>. They developed a simple model considering the transition between latently infected and activated T cells. The results demonstrated that viral dynamics in patients under HAART might be consistent with low-level viral replication but the replication did not have much impact on the decay rate of the latent reservoir, which confirms their earlier modeling predictions <xref ref-type="bibr" rid="pcbi.1000533-Sedaghat2">[32]</xref>. Mathematical models have also been proposed to test possible mechanisms for the generation of viral blips. Jones and Perelson showed that activation of either target T cells <xref ref-type="bibr" rid="pcbi.1000533-Jones2">[33]</xref> or latently infected cells <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref> could result in a burst of virus production. Asymmetric division of activated latently infected cells may explain the variable decay kinetics of the latent reservoir and intermittent viral blips <xref ref-type="bibr" rid="pcbi.1000533-Rong2">[34]</xref>.</p>
<p>In this paper, we further study latently infected cell activation in response to antigenic stimulation by extending the models in <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Kim1">[30]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Jones2">[33]</xref>. We examine the hypothesis that stochastic activation of latently infected cells can generate intermittent viral blips and maintain low-level plasma viremia, without seriously depleting the latent reservoir in patients under HAART. The model focuses on the response of latently infected cells when they encounter their relevant antigens. We show that programmed expansion and contraction of latently infected cells can generate intermittent viral blips with realistic amplitude and duration. During the latent T cell response, part of the resultant activated T cell population reverts back to a resting state, providing a mechanism to replenish the latent reservoir. An interesting result of our model is that different potentials of activated T cells to proliferate during the response or different duration or frequency of antigenic stimulation can explain the differences between the divergent estimates of the half-life of the latent reservoir decay in HAART-treated patients <xref ref-type="bibr" rid="pcbi.1000533-Finzi3">[21]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1000533-Chun5">[35]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Zhang1">[38]</xref>. Using this model, we study the influence of ongoing viral replication on both the decay of the latent reservoir and persistence of low-level viremia. We perform sensitivity tests on a number of model parameters. Finally, we develop a phenomenological model that postulates density-dependent homeostatic proliferation of resting memory <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e004" xlink:type="simple"/></inline-formula> T cells. A recent experimental study supports the idea that homeostatic proliferation of latently infected cells may ensure the latent reservoir persistence without any demonstrable evidence for viral production <xref ref-type="bibr" rid="pcbi.1000533-Chomont1">[39]</xref>. The model can robustly describe the multiphasic viral decline following initiation of potent antiretroviral treatment. The different self-renewal potentials of latently infected cells are also able to reconcile the variable decay kinetics of the latent reservoir. Our models provide a new perspective into the possible mechanisms for viral and the latent reservoir persistence and emergence of intermittent viral blips.</p>
</sec><sec id="s2">
<title>Methods</title>
<sec id="s2a">
<title>A basic model of latent cell activation</title>
<p>A basic model of latent cell activation was initially developed to examine the cell populations contributing to the second-phase viral decline after administration of both reverse transcriptase (RT) and protease inhibitors <xref ref-type="bibr" rid="pcbi.1000533-Perelson1">[4]</xref>. Using an overall drug efficacy, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e005" xlink:type="simple"/></inline-formula>, the basic model can be reduced to the simpler form <xref ref-type="bibr" rid="pcbi.1000533-Rong2">[34]</xref>:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e006" xlink:type="simple"/><label>(1)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e007" xlink:type="simple"/></inline-formula> represents <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e008" xlink:type="simple"/></inline-formula> T cells that are susceptible to HIV-1 infection, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e009" xlink:type="simple"/></inline-formula> represents productively infected cells that can produce virus particles, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e010" xlink:type="simple"/></inline-formula> represents latently infected cells that cannot produce virus but are ready to do so once they are activated by their recall antigens, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e011" xlink:type="simple"/></inline-formula> represents the total viral load. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e012" xlink:type="simple"/></inline-formula> is the recruitment rate of susceptible T cells and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e013" xlink:type="simple"/></inline-formula> is their mortality rate. The constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e014" xlink:type="simple"/></inline-formula> is the infection rate. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e015" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e016" xlink:type="simple"/></inline-formula> are the death rate of productively and latently infected cells, respectively. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e017" xlink:type="simple"/></inline-formula> is the clearance rate of free virus. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e018" xlink:type="simple"/></inline-formula> is the burst size, the total number of virions produced by an infected cell during its life span. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e019" xlink:type="simple"/></inline-formula> is the fraction of infections that lead to latency. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e020" xlink:type="simple"/></inline-formula> is the transition rate at which latently infected cells become productively infected cells. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e021" xlink:type="simple"/></inline-formula> is the total drug efficacy, which is defined as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e022" xlink:type="simple"/></inline-formula> where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e023" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e024" xlink:type="simple"/></inline-formula> are the drug efficacy of RT and protease inhibitor, respectively.</p>
<p>There is only one positive steady state viral load of Eq. (1):<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e025" xlink:type="simple"/><label>(2)</label></disp-formula>It is biologically plausible if and only if <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e026" xlink:type="simple"/></inline-formula> is less than a “critical efficacy”, given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e027" xlink:type="simple"/><label>(3)</label></disp-formula>If <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e028" xlink:type="simple"/></inline-formula>, then the only steady state is the uninfected steady state, with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e029" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e030" xlink:type="simple"/></inline-formula>. The steady state viral load (2) can theoretically achieve any positive value close to zero. However, it remains very sensitive to small changes of drug efficacy, particularly when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e031" xlink:type="simple"/></inline-formula> approaches <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e032" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Rong2">[34]</xref>. Therefore, the basic model and its various variations <xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref> are not realistic to describe the persistence of low-level viremia in patients on HAART. Furthermore, the model cannot maintain the latent reservoir size unless the death rate of latently infected cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e033" xlink:type="simple"/></inline-formula> and the transition rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e034" xlink:type="simple"/></inline-formula> are both chosen to be very small <xref ref-type="bibr" rid="pcbi.1000533-Sedaghat1">[31]</xref>. If transient episodes of viremia also come from activation of latently infected cells as suggested in <xref ref-type="bibr" rid="pcbi.1000533-Tobin1">[40]</xref>, then the latent reservoir will be depleted more quickly than observed in clinical studies.</p>
</sec><sec id="s2b">
<title>Model with programmed expansion and contraction of latently infected cells upon activation</title>
<p>Both <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e035" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e036" xlink:type="simple"/></inline-formula> T cell responses to infectious agents (for example, lymphocytic choriomeningitis virus (LCMV) <xref ref-type="bibr" rid="pcbi.1000533-Homann1">[41]</xref> and Listeria monocytogenes <xref ref-type="bibr" rid="pcbi.1000533-Pamer1">[42]</xref>) can be broken down into three distinct phases: expansion/activation, contraction/death and maintenance/memory <xref ref-type="bibr" rid="pcbi.1000533-Ahmed1">[43]</xref>. Upon initial exposure to antigen, specific T cells undergo considerable antigen-driven expansion and differentiation into effector cells, whose major function is to kill infected cells. A contraction or death phase then ensues, in which the majority of activated T cells die quickly by apoptosis or activation-induced cell death. The third phase is characterized by a stable <xref ref-type="bibr" rid="pcbi.1000533-DeBoer1">[44]</xref> or slowly decaying pool <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref> of memory cells, which are formed during the response and are maintained for long periods of time. By developing mathematical models considering these phases, De Boer et al. studied the dynamics of the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e037" xlink:type="simple"/></inline-formula> T cell response to LCMV <xref ref-type="bibr" rid="pcbi.1000533-DeBoer1">[44]</xref> and compared them with the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e038" xlink:type="simple"/></inline-formula> T cell response to LCMV <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref>. Fitting models to experimental data, they obtained the T cell doubling time during the expansion phase and the T cell half-life during the contraction phase. These results suggest that the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e039" xlink:type="simple"/></inline-formula> T cell response has faster kinetics in almost every aspect than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e040" xlink:type="simple"/></inline-formula> T cells <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref>. Jones and Perelson <xref ref-type="bibr" rid="pcbi.1000533-Jones2">[33]</xref> developed a model that accounts for both HIV infection and the programmed cascade of divisions during the expansion of the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e041" xlink:type="simple"/></inline-formula> T cell response to a concurrent opportunistic infection. Using the model, they showed that target cell activation <xref ref-type="bibr" rid="pcbi.1000533-Jones2">[33]</xref> or latent cell activation <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref> caused by opportunistic infections was able to explain the transient low-level viremia observed in well-suppressed patients on potent treatment. Here, we reexamine the model in <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref> and develop a new one in which latently infected cells are hypothesized to experience programmed expansion and contraction in response to their specific antigens, and in which a small portion of activated cells revert back to the resting state by the process that normally generates memory <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e042" xlink:type="simple"/></inline-formula> T cells (<xref ref-type="fig" rid="pcbi-1000533-g002">Figure 2</xref>). We investigate whether repeated latent cell activation through this type of programmed response can generate intermittent viral blips with reasonable amplitude and duration, and whether the replenishment of latently infected cells can control the decay of the latent reservoir.</p>
<fig id="pcbi-1000533-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g002</object-id><label>Figure 2</label><caption>
<title>Schematic representation of the model with latently infected cell activation (Eq. (4)).</title>
<p>Following encounter with cell-specific antigens, latently infected cells are activated and undergo programmed clonal expansion and contraction. A number of activated latently infected cells transition to the productive class and produce virions, whereas another small fraction of activated cells revert back to the latent state, providing a mechanism to replenish the latent reservoir.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g002" xlink:type="simple"/></fig>
<p>Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e043" xlink:type="simple"/></inline-formula> represent the concentration of resting latently infected <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e044" xlink:type="simple"/></inline-formula> T cells. These cells on encounter with their relevant antigens may enter the class of activated cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e045" xlink:type="simple"/></inline-formula>. One model describing the programmed expansion and contraction of latently infected cells upon antigenic stimulation is as follows:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e046" xlink:type="simple"/><label>(4)</label></disp-formula>When the antigen is present, resting latently infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e047" xlink:type="simple"/></inline-formula>, are activated into the activated class <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e048" xlink:type="simple"/></inline-formula> with rate constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e049" xlink:type="simple"/></inline-formula>. The function <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e050" xlink:type="simple"/></inline-formula> determines the times at which antigen is present at concentration sufficiently high to activate cells. Activated cells proliferate at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e051" xlink:type="simple"/></inline-formula>. Once the antigen concentration falls, we assume there is a contraction phase, in which activated cells die or apoptose at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e052" xlink:type="simple"/></inline-formula>, or revert to the resting state at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e053" xlink:type="simple"/></inline-formula>. In addition, activated latently infected cells transition into productively infected cells at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e054" xlink:type="simple"/></inline-formula> during the entire response.</p>
<p>As suggested by <xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Holte1">[46]</xref>, we use a density-dependent death rate of productively infected cells in order to reduce the sensitivity of the steady state viral load to changes of drug efficacy. The biological justification for the density-dependent cell death rate is as follows: productively infected cell can be killed at a rate that depends on the density of effector cells. The population size of effector cells can be further assumed to be proportional to the density of infected cells. Thus, the death rate of productively infected cells can be assumed to be a function of the infected cell density. We choose a simple power-law function, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e055" xlink:type="simple"/></inline-formula>, as used in <xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Holte1">[46]</xref>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e056" xlink:type="simple"/></inline-formula> controls the size of the immune effect on the death rate. Holte et al. <xref ref-type="bibr" rid="pcbi.1000533-Holte1">[46]</xref> obtained estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e057" xlink:type="simple"/></inline-formula> by fitting the density-dependent decay model to patient data. Because the model includes a density-dependent infected cell death rate, we have to decouple the viral production rate from the cell death rate. We assume virus is produced at a constant rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e058" xlink:type="simple"/></inline-formula>, per productively infected cell, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e059" xlink:type="simple"/></inline-formula>. For simplicity, we assume <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e060" xlink:type="simple"/></inline-formula>. A modification of this model will be given later to study viral persistence without the assumption of density-dependent infected cell death.</p>
<p>We employ a basic “on-off” model, which has previously been used to describe the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e061" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e062" xlink:type="simple"/></inline-formula> T cell responses to viral infection <xref ref-type="bibr" rid="pcbi.1000533-DeBoer1">[44]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref>, to approximate the antigenic stimulation of latently infected cells instead of explicitly modeling the interaction between naive T cells and their specific antigens as was done in <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Jones2">[33]</xref>. The activation function, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e063" xlink:type="simple"/></inline-formula>, is antigen-dependent and takes on only two values: 0 if there is no activation, and 1 if there is full activation. If <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e064" xlink:type="simple"/></inline-formula> is the time at which the stimulation switches “on” and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e065" xlink:type="simple"/></inline-formula> is the time at which the stimulation is “off”, then <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e066" xlink:type="simple"/></inline-formula> assumes the following expression:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e067" xlink:type="simple"/><label>(5)</label></disp-formula>We denote by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e068" xlink:type="simple"/></inline-formula> the duration that each activation lasts.</p>
<p>Although <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e069" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e070" xlink:type="simple"/></inline-formula> T cells both commit to clonal expansion after antigenic stimulation, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e071" xlink:type="simple"/></inline-formula> T cells typically have a higher proliferative potential both <italic>in vitro</italic> and <italic>in vivo</italic> compared with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e072" xlink:type="simple"/></inline-formula> T cells <xref ref-type="bibr" rid="pcbi.1000533-Homann1">[41]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Kaech1">[47]</xref>. It has been estimated that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e073" xlink:type="simple"/></inline-formula> T cells divide about <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e074" xlink:type="simple"/></inline-formula> times during an acute infection with LCMV, while <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e075" xlink:type="simple"/></inline-formula> T cells divide approximately 9 times <xref ref-type="bibr" rid="pcbi.1000533-Homann1">[41]</xref>. Choosing the proliferation rate of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e076" xlink:type="simple"/></inline-formula> T cells as in <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e077" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e078" xlink:type="simple"/></inline-formula> T cells can divide 8 to 12 times if the expansion phase lasts <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e079" xlink:type="simple"/></inline-formula> days. If <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e080" xlink:type="simple"/></inline-formula>, then <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e081" xlink:type="simple"/></inline-formula> T cells only divide 5 to 7 times over the same period. With various proliferation rates, we will show that the number of times that activated latently infected cells divide upon stimulation is an influential factor that not only controls the decay of the latent reservoir but that also affects the amplitude of viral blips. Because only a small fraction of latently infected cells are specific for any given antigen, we choose <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e082" xlink:type="simple"/></inline-formula> to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e083" xlink:type="simple"/></inline-formula>. We will perform sensitivity tests on a few parameters including <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e084" xlink:type="simple"/></inline-formula>. The death rate of activated cells during the contraction phase, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e085" xlink:type="simple"/></inline-formula>, is not well-known. In <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref>, about <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e086" xlink:type="simple"/></inline-formula> was estimated for this parameter. Because the cells activated from latently infected cells are usually not observed, here we choose a larger death rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e087" xlink:type="simple"/></inline-formula>, such that activated latently infected cells will decline to low levels after a relatively short period. We will discuss the effect of a smaller <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e088" xlink:type="simple"/></inline-formula> later. We also assume that a small fraction of activated cells revert back to the resting state, with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e089" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>, whereas another portion of them transition into the productive stage with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e090" xlink:type="simple"/></inline-formula>. We will test our model predictions with different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e091" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e092" xlink:type="simple"/></inline-formula>.</p>
<p>We choose the overall drug efficacy <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e093" xlink:type="simple"/></inline-formula> as the baseline value so that viral load can be suppressed to below the detection limit after several months of treatment. In fact, as we will show below, specific values of the drug efficacy do not strongly impact viral and the latent reservoir persistence once it exceeds a threshold called the critical efficacy. The dynamics of viral load, the latent reservoir and viral blips will also be compared with different drug efficacies. Similar arguments can be applied to the choice of the value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e094" xlink:type="simple"/></inline-formula>, the fraction of infections resulting in latency. As long as it represents a small fraction of infections, the value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e095" xlink:type="simple"/></inline-formula> has only a minor effect. Here we choose <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e096" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref> as an example. The form of the activation function <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e097" xlink:type="simple"/></inline-formula> will be further discussed below. The viral burst size, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e098" xlink:type="simple"/></inline-formula>, can affect the amplitude of blips generated from activation of latently infected cells. Here we use <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e099" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-Hockett1">[48]</xref>, although recently higher values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e100" xlink:type="simple"/></inline-formula> have been estimated for SIV <xref ref-type="bibr" rid="pcbi.1000533-Chen1">[49]</xref>. It is not known if these higher burst sizes apply to HIV. However, if higher values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e101" xlink:type="simple"/></inline-formula> are used, then other parameters in <xref ref-type="table" rid="pcbi-1000533-t001">Table 1</xref> need to be adjusted, such as the viral clearance rate, which recent work suggests may be higher in tissue than has been estimated in blood (De Boer R., Ribeiro R. and Perelson AS, unpublished results). The other parameter values are chosen based on previously published reports and are summarized in <xref ref-type="table" rid="pcbi-1000533-t001">Table 1</xref>.</p>
<table-wrap id="pcbi-1000533-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.t001</object-id><label>Table 1</label><caption>
<title>Variables, parameters and values used in models and simulations.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000533-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.t001" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Variable/Parameter</td>
<td align="left" colspan="1" rowspan="1">Value</td>
<td align="left" colspan="1" rowspan="1">Description</td>
<td align="left" colspan="1" rowspan="1">Reference</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e102" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Target T cells</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e103" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Latently infected cells</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e104" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Resting latently infected cells</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e105" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Activated latently infected cells</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e106" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Productively infected cells</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e107" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">Viral load</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e108" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e109" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Recruitment rate of susceptible cells</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e110" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e111" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Death rate of susceptible cells</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Mohri1">[90]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e112" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e113" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Infection rate</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Perelson2">[50]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e114" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">0.85</td>
<td align="left" colspan="1" rowspan="1">Overall drug efficacy</td>
<td align="left" colspan="1" rowspan="1">see text</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e115" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e116" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Fraction resulting in latency</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e117" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e118" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Death rate of latently infected cells</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e119" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e120" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Rate of transition from latently to</td>
<td align="left" colspan="1" rowspan="1">see text</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1">productively infected cells</td>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e121" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e122" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Death rate of productively infected cells</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Markowitz1">[91]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e123" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e124" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Burst size</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Hockett1">[48]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e125" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e126" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Clearance rate of free virus</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Ramratnam3">[92]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e127" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e128" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Density-dependent mortality</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e129" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e130" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Power in density-dependent mortality function</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Holte1">[46]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e131" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e132" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Viral production rate</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Hockett1">[48]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e133" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">varied</td>
<td align="left" colspan="1" rowspan="1">Proliferation rate of activated cells</td>
<td align="left" colspan="1" rowspan="1">see text</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e134" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e135" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Activation rate of latent cells</td>
<td align="left" colspan="1" rowspan="1">see text</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e136" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e137" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Death rate of activated cells</td>
<td align="left" colspan="1" rowspan="1">see text</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e138" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e139" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Reversion rate to latency</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e140" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e141" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">Base death rate of activated cells</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e142" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">varied</td>
<td align="left" colspan="1" rowspan="1">Maximum proliferation rate of latent cells</td>
<td align="left" colspan="1" rowspan="1">see text</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e143" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">varied</td>
<td align="left" colspan="1" rowspan="1">Carrying capacity density of latent cells</td>
<td align="left" colspan="1" rowspan="1">see text</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e144" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">see text</td>
<td align="left" colspan="1" rowspan="1">Expansion function</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e145" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">see text</td>
<td align="left" colspan="1" rowspan="1">Rapid contraction function</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
</tbody>
</table></alternatives></table-wrap>
<p>Since we are interested in the dynamics of the third-phase viral decline during treatment, we choose the initial viral load to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e146" xlink:type="simple"/></inline-formula>. With an assumption of quasi-steady state between virions and productively infected cells, we obtain the initial condition for productively infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e147" xlink:type="simple"/></inline-formula>. We set <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e148" xlink:type="simple"/></inline-formula> as the initial condition for target T cells <xref ref-type="bibr" rid="pcbi.1000533-Kim1">[30]</xref>. The total number of latently infected cells with replication-competent viral genomes is assumed to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e149" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-Chun1">[15]</xref>, 98% of which are in the lymphoid tissue and the rest are in the blood. Assuming the blood volume is 5 L, the concentration of latently infected cells with replication-competent provirus is 2 cells/mL, i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e150" xlink:type="simple"/></inline-formula>. We assume there are no activated latently infected cells initially, i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e151" xlink:type="simple"/></inline-formula>.</p>
</sec><sec id="s2c">
<title>Model with a biphasic contraction phase</title>
<p>Homann et al. <xref ref-type="bibr" rid="pcbi.1000533-Homann1">[41]</xref> suggested a multiphasic contraction phase in the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e152" xlink:type="simple"/></inline-formula> T cell response to acute LCMV infection. De Boer et al. <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref> developed a mathematical model that fits the Homann data using two distinct phases of activated cell death after the peak of the response. Here, we modify model (4) by adopting a biphasic contraction phase in the latently infected <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e153" xlink:type="simple"/></inline-formula> T cell response. More motivations will be addressed in the <xref ref-type="sec" rid="s3">Results</xref> section after we present the results of model (4). In the modified model, the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e154" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e155" xlink:type="simple"/></inline-formula> equations remain the same, while the other equations change to<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e156" xlink:type="simple"/><label>(6)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e157" xlink:type="simple"/></inline-formula> is the expansion function defined by Eq. (5). Following the expansion phase, there is a two-phase contraction: a rapid contraction phase of length <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e158" xlink:type="simple"/></inline-formula>, where activated cells die rapidly by apoptosis or activation-induced cell death, at a rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e159" xlink:type="simple"/></inline-formula>, and a slower phase where activated cells die at their base mortality rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e160" xlink:type="simple"/></inline-formula>. For simplicity, we assume the rapid contraction phase has the same length as the expansion phase (i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e161" xlink:type="simple"/></inline-formula>). <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e162" xlink:type="simple"/></inline-formula> represents the contraction function. During the rapid contraction phase, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e163" xlink:type="simple"/></inline-formula>, otherwise, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e164" xlink:type="simple"/></inline-formula>.</p>
</sec><sec id="s2d">
<title>A phenomenological model with homeostasis of latently infected cells</title>
<p>A recent experimental study by Chomont et al. <xref ref-type="bibr" rid="pcbi.1000533-Chomont1">[39]</xref> shows that the HIV-1 latent reservoir size may be maintained by homeostatic proliferation of latently infected cells. Thus, we incorporate a logistic term representing homeostatic proliferation of latently infected cells into the basic model (1). The <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e165" xlink:type="simple"/></inline-formula> equation becomes<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e166" xlink:type="simple"/><label>(7)</label></disp-formula>The other equations for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e167" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e168" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e169" xlink:type="simple"/></inline-formula> are the same as those in model (1). In Eq. (7), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e170" xlink:type="simple"/></inline-formula> represents the maximum proliferation rate and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e171" xlink:type="simple"/></inline-formula> represents a threshold latent cell density, beyond which proliferation shuts off. Whether there is such a strict maximum is unclear and thus other forms of density-dependent proliferation could also be explored, such as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e172" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e173" xlink:type="simple"/></inline-formula> is a constant.</p>
<p>We choose a small base value for the transition rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e174" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>, because only a small fraction of latently infected cells are specific for any given antigen. We will increase the value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e175" xlink:type="simple"/></inline-formula> when we study latently infected cells encountering their specific antigens, which is used to model emergence of viral blips during treatment.</p>
<p>In order to maintain the latent cell pool during potent drug therapy, we choose the proliferation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e176" xlink:type="simple"/></inline-formula> to be greater than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e177" xlink:type="simple"/></inline-formula>, i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e178" xlink:type="simple"/></inline-formula>. In fact, it can be proved that in the case of 100% drug effectiveness, the infected steady state exists and is locally asymptotically stable if and only if <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e179" xlink:type="simple"/></inline-formula>.</p>
<p>The carrying capacity (i.e., the maximum sustainable population) of latently infected cells during therapy is unknown. Assuming <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e180" xlink:type="simple"/></inline-formula> total body lymphocytes, Chun et al. <xref ref-type="bibr" rid="pcbi.1000533-Chun1">[15]</xref> reported a total body load of resting <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e181" xlink:type="simple"/></inline-formula> T cells with integrated HIV-1 DNA of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e182" xlink:type="simple"/></inline-formula> cells during the asymptomatic phase of infection. Here we allow the total body carrying capacity of latently infected cells to vary from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e183" xlink:type="simple"/></inline-formula> cells to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e184" xlink:type="simple"/></inline-formula> cells but then convert these numbers to a cell density in blood so as to be in the same units as the target cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e185" xlink:type="simple"/></inline-formula>. For example, if there are maximally <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e186" xlink:type="simple"/></inline-formula> latently infected cells per patient under HAART, then the maximum density of latently infected cells in blood is <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e187" xlink:type="simple"/></inline-formula> since <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e188" xlink:type="simple"/></inline-formula> of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e189" xlink:type="simple"/></inline-formula> T cells are in blood and the typical 70 kg individual has about 5L of blood. We will discuss the effects of different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e190" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e191" xlink:type="simple"/></inline-formula> on the final model predictions.</p>
<p>The simulation with an initial T cell count <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e192" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-Perelson2">[50]</xref> and an arbitrary initial viral load value <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e193" xlink:type="simple"/></inline-formula> yields a set of steady state values in the absence of drug treatment: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e194" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e195" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e196" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e197" xlink:type="simple"/></inline-formula>. These values are set as the initial conditions when performing simulations of the model during HAART.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Intermittent viral blips and decay of the latent reservoir</title>
<p>Numerical simulations of model (4) show that programmed expansion and contraction of latently infected cells upon occasional antigenic stimulation can robustly generate intermittent viral blips with reasonable amplitude and duration, without seriously depleting the latent reservoir (<xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3</xref>). We assume that latently infected cells encounter their specific antigens randomly. As an example, we assume the interval between two adjacent activations, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e198" xlink:type="simple"/></inline-formula>, obeys a normal distribution with a mean of 50 days and a standard deviation of 10 days. If we use a Poisson process to model the encounter between latently infected cells and antigen, then we get a similar pattern of viral blips and the latent reservoir decay when the average waiting time between two encounters is assumed to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e199" xlink:type="simple"/></inline-formula> days. The duration of activated T cell proliferation during the latent cell response remains unknown. In fact, the mechanisms that control the rate and extent of T cell differentiation are complicated <xref ref-type="bibr" rid="pcbi.1000533-Kaech1">[47]</xref>. It may involve the amount of antigen and other types of cytokines that are present <italic>in vivo</italic>, the duration of antigen exposure, as well as whether T cell proliferation continues in the absence of further antigenic stimulation <xref ref-type="bibr" rid="pcbi.1000533-Iezzi1">[51]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Kundig1">[54]</xref>. In our simulation, we assume the duration of activated T cell proliferation, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e200" xlink:type="simple"/></inline-formula>, obeys a uniform distribution over the interval of 4 to 6 days such that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e201" xlink:type="simple"/></inline-formula> T cells divide approximately 5 to 12 times with appropriate proliferation rates (see below) <xref ref-type="bibr" rid="pcbi.1000533-Homann1">[41]</xref>. A transient episode of viremia is observed every time an activation occurs. Thus, the timing and frequency of viral blips are determined by when and how often latently infected cells encounter their recall antigens. The duration of transient viremia is determined by how long the antigen is present (<xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3</xref>). Another important characteristic of viral blips, the amplitude, ranges from 50 RNA copies/mL to roughly 500 copies/mL in our simulations. This is consistent with observations in clinical trials <xref ref-type="bibr" rid="pcbi.1000533-DiMascio2">[24]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Nettles1">[26]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Greub1">[55]</xref>.</p>
<fig id="pcbi-1000533-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g003</object-id><label>Figure 3</label><caption>
<title>Stochastic simulations of the model with programmed expansion and contraction (Eq. (4)).</title>
<p>The model with programmed expansion and contraction of latently infected cells can generate viral blips with reasonable amplitude and duration. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e202" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e203" xlink:type="simple"/></inline-formula>. Column <bold>A:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e204" xlink:type="simple"/></inline-formula>. Activated latently infected cells divide about <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e205" xlink:type="simple"/></inline-formula> times over an interval <xref ref-type="bibr" rid="pcbi.1000533-Perelson1">[4]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Hammer1">[6]</xref> days. No statistically significant decay of the latent reservoir is observed. Column <bold>B:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e206" xlink:type="simple"/></inline-formula>. The latent reservoir decays at a very slow rate. This realization shows a half-life of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e207" xlink:type="simple"/></inline-formula> months. Column <bold>C:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e208" xlink:type="simple"/></inline-formula>. Activated cells divide about <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e209" xlink:type="simple"/></inline-formula> times over the same time interval. The latent reservoir decays more quickly than it does in <bold>B</bold>, corresponding to a half-life of roughly <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e210" xlink:type="simple"/></inline-formula> months. The other parameter values used are listed in <xref ref-type="table" rid="pcbi-1000533-t001">Table 1</xref>. The blue horizontal line represents the detection limit of 50 RNA copies/mL.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g003" xlink:type="simple"/></fig>
<p>An interesting result is that the amplitude of viral blips is inversely correlated with the decay of the latent reservoir. Based on model (4), viral blips originate from activation of latently infected cells into the productive class. It was initially thought that this activation would deplete the latent reservoir quickly in HAART-treated patients because <italic>de novo</italic> infection of susceptible T cells is maximally inhibited by potent antiretroviral drugs and productively infected cells have a fast turnover rate. However, if the activation induces a substantial proliferation of activated latently infected cells, it can simultaneously reseed the latent reservoir as a small fraction of activated cells revert to the resting state in the formation of memory T cells. To what extent the activation replenishes the latent cell pool depends heavily on the proliferative potential of activated cells, i.e., how many daughter cells are derived from the activation of latently infected cells. In <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>A</bold></xref>, the proliferation rate of activated cells is chosen to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e211" xlink:type="simple"/></inline-formula>, which implies that cell divisions occur <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e212" xlink:type="simple"/></inline-formula> times over an interval of 4 to 6 days. In this case, the activation induces a high level of activated T cells. As a consequence, a large number of productively infected cells are generated. Thus, the amplitude of viral blips remains relatively high, and the latent reservoir is largely replenished since more activated latently infected cells revert back to the resting state. In our simulation, we did not observe a statistically significant decay of the latent reservoir (we performed the simulation over 3 years, but only plotted the first 300 days in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>A</bold></xref>), suggesting that the viral reservoir can be extremely stable even with effective treatment for years. This may explain the remarkable stability of the latent reservoir in some patients on HAART <xref ref-type="bibr" rid="pcbi.1000533-Finzi3">[21]</xref>. In <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>B</bold></xref>, we show an example with a slightly smaller proliferation rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e213" xlink:type="simple"/></inline-formula>. In this situation, although occasional activation can replenish the latent reservoir, the size of the latent cell pool diminishes gradually. However, the decay is very slow, with a half-life of approximately 44 months, which is consistent with some estimates <xref ref-type="bibr" rid="pcbi.1000533-Finzi3">[21]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Siliciano1">[22]</xref>. In <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>C</bold></xref>, we choose the proliferation rate to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e214" xlink:type="simple"/></inline-formula>, so that activated T cells divide <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e215" xlink:type="simple"/></inline-formula> times over an interval of 4 to 6 days. In this case, a lower level of activated cells are produced, resulting in lower amplitude viral blips. The latent reservoir is depleted relatively quickly because cell activation consumes latently infected cells and the replenishment of the reservoir from activated cells is minor. <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>C</bold></xref> shows a realization of model (4) in which the decay half-life of the latent reservoir is about 6 months, which is in agreement with the estimates in some clinical studies <xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Zhang1">[38]</xref>.</p>
<p>We ran stochastic simulations of the model 30 times, recorded the number and amplitudes of viral blips, and calculated the half-life of the decay of the latent reservoir based on the change in the latent reservoir size in 300 days. The summary statistics on our simulations is given in <xref ref-type="table" rid="pcbi-1000533-t002">Table 2</xref>. As the proliferation rate of activated cells <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e216" xlink:type="simple"/></inline-formula> decreases, we observe that both the frequency and the average amplitude of viral blips decrease. With a smaller <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e217" xlink:type="simple"/></inline-formula>, the latent reservoir size undergoes a larger decrease, corresponding to a shorter half-life of the reservoir decay. Thus, we expect an inverse relationship between the decay of the latent reservoir and the frequency (or amplitude) of viral blips. This is consistent with the experimental observations in Ramratnam et al. <xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>.</p>
<table-wrap id="pcbi-1000533-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.t002</object-id><label>Table 2</label><caption>
<title>Summary of stochastic simulations of the model, Eq. (4), with programmed expansion and contraction of latently infected cells.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000533-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.t002" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Parameter value</td>
<td align="left" colspan="1" rowspan="1">Ave number of blips over [0, 300] days</td>
<td align="left" colspan="1" rowspan="1">Min blip amplitude (copies/mL)</td>
<td align="left" colspan="1" rowspan="1">Max blip amplitude (copies/mL)</td>
<td align="left" colspan="1" rowspan="1">Ave blip amplitude (copies/mL)</td>
<td align="left" colspan="1" rowspan="1">Change in the latent reservoir size over 300 days</td>
<td align="left" colspan="1" rowspan="1">Half-life of the latent reservoir decay (months)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e218" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">186 [140, 362]</td>
<td align="left" colspan="1" rowspan="1">693 [541, 877]</td>
<td align="left" colspan="1" rowspan="1">394 [298, 522]</td>
<td align="left" colspan="1" rowspan="1">−0.5% [−19%, +26%]</td>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e219" xlink:type="simple"/></inline-formula> [33, -]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e220" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">168 [113, 308]</td>
<td align="left" colspan="1" rowspan="1">524 [346, 680]</td>
<td align="left" colspan="1" rowspan="1">334 [263, 446]</td>
<td align="left" colspan="1" rowspan="1">−14% [−32%, +5.5%]</td>
<td align="left" colspan="1" rowspan="1">46 [18, -]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e221" xlink:type="simple"/></inline-formula></td>
<td align="left" colspan="1" rowspan="1">3.7 [2, 5]</td>
<td align="left" colspan="1" rowspan="1">61 [50, 94]</td>
<td align="left" colspan="1" rowspan="1">93 [71, 111]</td>
<td align="left" colspan="1" rowspan="1">74 [63, 98]</td>
<td align="left" colspan="1" rowspan="1">−65% [−67%, −62%]</td>
<td align="left" colspan="1" rowspan="1">6.6 [6.3, 7.3]</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt101"><p>Abbreviations: ave (average), min (minimum), max (maximum). Values above brackets are the average values over 30 simulation runs. Values in brackets are the ranges. There are 5 antigenic activations within 300 days. When <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e222" xlink:type="simple"/></inline-formula> or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e223" xlink:type="simple"/></inline-formula>, viral blip <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e224" xlink:type="simple"/></inline-formula> emerges each time activation occurs. When <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e225" xlink:type="simple"/></inline-formula>, not every activation generates a viral blip. In some simulations with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e226" xlink:type="simple"/></inline-formula> or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e227" xlink:type="simple"/></inline-formula>, the latent reservoir size is predicted to increase and hence has no half-life.</p></fn></table-wrap-foot></table-wrap>
<p>The fraction of resting latently infected cells that are activated by antigenic stimulation remains largely unknown. Due to the heterogeneity of latently infected cells with respect to the antigens they respond to, it is likely that a very small fraction of latently infected cells are activated by a particular antigen. We tested model predictions (Eq. (4)) with different activation rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e228" xlink:type="simple"/></inline-formula>. The proliferation rate of activated cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e229" xlink:type="simple"/></inline-formula>, is fixed. With <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e230" xlink:type="simple"/></inline-formula> decreasing from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e231" xlink:type="simple"/></inline-formula> (red solid) to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e232" xlink:type="simple"/></inline-formula> (black dotted) in <xref ref-type="fig" rid="pcbi-1000533-g004">Figure 4<bold>A</bold></xref>, fewer activated latently infected cells are generated, which results in a more rapid decay of the latent reservoir and lower viral loads. In fact, when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e233" xlink:type="simple"/></inline-formula>, 5 activations only generate 3 viral rebounds, in which only 2 rebounds can be regarded as viral blips <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e234" xlink:type="simple"/></inline-formula>. With a smaller <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e235" xlink:type="simple"/></inline-formula> (e.g., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e236" xlink:type="simple"/></inline-formula>), antigenic activation cannot generate viral blips with the parameter values we used. We also tested the sensitivity of generating blips to the transition rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e237" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000533-g004">Figure 4<bold>B</bold></xref>). When <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e238" xlink:type="simple"/></inline-formula> decreases from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e239" xlink:type="simple"/></inline-formula> (red solid) to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e240" xlink:type="simple"/></inline-formula> (black dotted), the viral load does not change significantly. However, a smaller transition rate leads to more substantial replenishment of the latent reservoir. Viral load also depends on the viral production rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e241" xlink:type="simple"/></inline-formula>. For example, when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e242" xlink:type="simple"/></inline-formula>, only 2 viral blips are observed with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e243" xlink:type="simple"/></inline-formula> (black dotted in <xref ref-type="fig" rid="pcbi-1000533-g004">Figure 4<bold>C</bold></xref>). If we increase the viral production rate to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e244" xlink:type="simple"/></inline-formula> (red solid), then all the 3 rebounds are greater than 50 RNA copies/mL and thus generate observable viral blips.</p>
<fig id="pcbi-1000533-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g004</object-id><label>Figure 4</label><caption>
<title>Sensitivity tests on the activation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e245" xlink:type="simple"/></inline-formula> and the transition rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e246" xlink:type="simple"/></inline-formula> in Eq. (4).</title>
<p>The proliferation rate of activated cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e247" xlink:type="simple"/></inline-formula>, is fixed. Column <bold>A:</bold> the transition rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e248" xlink:type="simple"/></inline-formula> is fixed and the activation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e249" xlink:type="simple"/></inline-formula> varies: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e250" xlink:type="simple"/></inline-formula> (red solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e251" xlink:type="simple"/></inline-formula> (blue dashed) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e252" xlink:type="simple"/></inline-formula> (black dotted). <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e253" xlink:type="simple"/></inline-formula> is fixed. Column <bold>B:</bold> the activation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e254" xlink:type="simple"/></inline-formula> is fixed and the transition rate varies: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e255" xlink:type="simple"/></inline-formula> (red solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e256" xlink:type="simple"/></inline-formula> (blue dashed) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e257" xlink:type="simple"/></inline-formula> (black dotted). <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e258" xlink:type="simple"/></inline-formula> is fixed. Column <bold>C:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e259" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e260" xlink:type="simple"/></inline-formula> are fixed. The viral production rate varies: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e261" xlink:type="simple"/></inline-formula> (red solid) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e262" xlink:type="simple"/></inline-formula> (black dotted). The other parameter values used are the same as those in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3</xref>. The blue horizontal line represents the detection limit of 50 RNA copies/mL.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g004" xlink:type="simple"/></fig>
<p>In addition to changing the proliferation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e263" xlink:type="simple"/></inline-formula> during expansion, it would also be interesting to study the effects of varying the duration <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e264" xlink:type="simple"/></inline-formula> and frequency (determined by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e265" xlink:type="simple"/></inline-formula>) of antigenic stimulation. As an example, we showed in <xref ref-type="fig" rid="pcbi-1000533-g005">Figures 5<bold>A</bold> and 5<bold>B</bold></xref> the latent reservoir decay and viral blips with different distributions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e266" xlink:type="simple"/></inline-formula>. Specifically, we assumed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e267" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1000533-g005">Figure 5<bold>A</bold></xref> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e268" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1000533-g005">Figure 5<bold>B</bold></xref>. We fixed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e269" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e270" xlink:type="simple"/></inline-formula> as used in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>C</bold></xref>. No statistically significant decay of the latent reservoir is observed in <xref ref-type="fig" rid="pcbi-1000533-g005">Figure 5<bold>A</bold></xref>, while the latent resevoir decays at a very slow rate (with a half-life of approximately 44 months) in <xref ref-type="fig" rid="pcbi-1000533-g005">Figure 5<bold>B</bold></xref>. This is not surprising since shorter duration of activation results in generation of less activated latently infected cells, and thus less replenishment of the latent reservoir. In <xref ref-type="fig" rid="pcbi-1000533-g005">Figure 5<bold>C</bold></xref>, we assumed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e271" xlink:type="simple"/></inline-formula> as in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>C</bold></xref>, but increased the frequency of activation by assuming <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e272" xlink:type="simple"/></inline-formula>. In this realization, there are 8 activations in 300 days, more than the 5 activations in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>C</bold></xref>. We observe that the latent reservoir decays more quickly than in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>C</bold></xref>. In fact, for a large proliferation rate of activated cells (e.g., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e273" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3<bold>B</bold></xref>), increasing the frequency of activation will replenish the latent reservoir more frequently and thus decrease the decay rate of the latent reservoir, whereas for a small proliferation rate (e.g., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e274" xlink:type="simple"/></inline-formula>) and short duration of activation (e.g., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e275" xlink:type="simple"/></inline-formula>), increasing the frequency of activation will accelerate the latent reservoir decay (see <xref ref-type="fig" rid="pcbi-1000533-g003">Figures 3<bold>C</bold></xref> and <xref ref-type="fig" rid="pcbi-1000533-g005">5<bold>C</bold></xref>).</p>
<fig id="pcbi-1000533-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g005</object-id><label>Figure 5</label><caption>
<title>Numerical simulations of Eq. (4) with different duration and frequency of activation.</title> 
<p>We fixed the proliferation rate of activated cells to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e276" xlink:type="simple"/></inline-formula>.  Column <bold>A:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e277" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e278" xlink:type="simple"/></inline-formula>. No statistically significant decay of the latent reservoir is observed. Column <bold>B:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e279" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e280" xlink:type="simple"/></inline-formula>. The latent reservoir decays at a very slow rate. Column <bold>C:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e281" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e282" xlink:type="simple"/></inline-formula>. In this realization, there are 8 activations in 300 days. The latent reservoir decays more quickly than in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3C</xref>. The other parameter values used are the same as those in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3</xref>. The blue horizontal line represents the detection limit of 50 RNA copies/mL.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g005" xlink:type="simple"/></fig>
<p>In summary, occasional activation of latently infected cells upon stochastic antigen encounter is able to produce a large quantity of activated T cells temporarily, and thereby generate intermittent viral blips. The blip amplitude/frequency is inversely correlated with the decay of the latent reservoir. Using different potentials of activated T cells to divide during the initial clonal expansion phase or different duration or frequency of antigenic stimulation enables us to generate the different decay characteristics of the latent reservoir observed in different clinical studies <xref ref-type="bibr" rid="pcbi.1000533-Finzi3">[21]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1000533-Chun5">[35]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Zhang1">[38]</xref>.</p>
</sec><sec id="s3b">
<title>Low-level viral persistence</title>
<p>We have assumed a density-dependent mortality rate for productively infected cells in the model given by Eq. (4) in order to maintain a low steady state viral load when antigen is absent. The reason that viral loads decrease very quickly in the absence of activation in this model is that activated cells decline quickly to an extremely low level during the contraction phase, with not enough cells entering the productive stage. Even when we choose a smaller death rate of activated cells, for example, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e283" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref>, activated cells still quickly decline to a very low level. If activated cells can be maintained at a low level rather than decreasing to zero quickly during the contraction phase, then low steady state viral load persistence is possible without assuming density-dependent infected cell death. A study by Chun et al. <xref ref-type="bibr" rid="pcbi.1000533-Chun6">[56]</xref> revealed that a high level of HIV-1 proviral DNA persists in the activated <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e284" xlink:type="simple"/></inline-formula> T cell compartment in infected individuals on effective antiretroviral therapy with no detectable viremia in plasma for extended periods of time. Although some of the proviruses might be defective, spontaneous release of virus was detected without any activating stimuli during overnight culture <xref ref-type="bibr" rid="pcbi.1000533-Chun6">[56]</xref>. This observation argues for the persistence of infectious virus in activated <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e285" xlink:type="simple"/></inline-formula> cells in patients under effective treatment. Here we modify model (4) (i.e., remove the assumption of density-dependent infected cell death and adopt a biphasic contraction phase, see Eq. (6) in <xref ref-type="sec" rid="s2">Methods</xref>) and examine whether viral and the latent reservoir persistence, as well as intermittent viral blips, can be generated solely by occasional activation of latently infected cells upon encounter with relevant antigen.</p>
<p>With <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e286" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000533-DeBoer2">[45]</xref>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e287" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e288" xlink:type="simple"/></inline-formula>, we perform numerical simulations of the model with a biphasic contraction phase. As before, we choose different proliferation rates, i.e., (<bold>A</bold>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e289" xlink:type="simple"/></inline-formula>, (<bold>B</bold>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e290" xlink:type="simple"/></inline-formula>, (<bold>C</bold>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e291" xlink:type="simple"/></inline-formula>, to characterize different potentials of activated cells to proliferate during the phase of expansion. Similar to <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3</xref>, the simulation results shown in <xref ref-type="fig" rid="pcbi-1000533-g006">Figure 6</xref> exhibit three distinct decay profiles of the latent reservoir: (<bold>A</bold>) there is almost no decay; (<bold>B</bold>) the latent reservoir decays at a very slow rate; (<bold>C</bold>) the reservoir decays at a faster rate. The decay of the latent reservoir is inversely correlated with the amplitude or frequency of viral blips. The viral load does not decline to an unreasonably low level in the absence of antigenic stimulation. This low-level viremia is primarily maintained by a small number of activated cells that transition into the productive class during the second slower contraction phase. However, the absence of antigenic stimulation over a long time (more than 4 months in our simulation, figure not shown) will deplete activated cells, and the viral load will decrease to an extremely low level (below <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e292" xlink:type="simple"/></inline-formula>, a level that can be interpreted as viral extinction <xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref>). Therefore, in order to obtain a low level of viremia solely maintained by latently infected cell activation, there cannot exist a very long period in which no antigenic stimulation occurs.</p>
<fig id="pcbi-1000533-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g006</object-id><label>Figure 6</label><caption>
<title>Simulations of the model with a biphasic contraction phase (Eq. (6)).</title>
<p>The model is able to generate viral blips as well as low-level persistent viremia. The low-level viral load is maintained by a low level of activated latently infected cells during the second slower contraction phase in the latent cell response. In the first row, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e293" xlink:type="simple"/></inline-formula> is the expansion function (red) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e294" xlink:type="simple"/></inline-formula> is the rapid contraction function (blue). Different proliferation rates, i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e295" xlink:type="simple"/></inline-formula> (Column <bold>A</bold>), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e296" xlink:type="simple"/></inline-formula> (Column <bold>B</bold>), and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e297" xlink:type="simple"/></inline-formula> (Column <bold>C</bold>), result in differential decay characteristics of the latent reservoir as in <xref ref-type="fig" rid="pcbi-1000533-g003">Figure 3</xref>. The other parameter values used are listed in <xref ref-type="table" rid="pcbi-1000533-t001">Table 1</xref>. The blue horizontal line represents the detection limit of 50 RNA copies/mL.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g006" xlink:type="simple"/></fig></sec><sec id="s3c">
<title>The contribution of ongoing viral replication</title>
<p>The decay of the latent reservoir, the amplitude of viral blips, and the viral load below the limit of detection are not largely influenced by the effectiveness of the treatment as long as the overall drug efficacy is beyond a threshold value, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e298" xlink:type="simple"/></inline-formula>, the critical drug efficacy. For this model we could not obtain a closed-form solution for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e299" xlink:type="simple"/></inline-formula> but it is numerically similar to that defined in (3). In <xref ref-type="fig" rid="pcbi-1000533-g007">Figures 7<bold>A</bold> and 7<bold>B</bold></xref>, we explore the effects of HAART potency on the latent reservoir and low-level viremia by using different drug efficacies: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e300" xlink:type="simple"/></inline-formula> (red dashed line) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e301" xlink:type="simple"/></inline-formula> (blue solid line). Although 100% effectiveness may not be clinically feasible, we use an extreme case to illustrate the effect of latent cell activation. We observe that for the lower drug efficacy, the latent reservoir and the viral load are both at slightly higher levels. However, the difference is minuscule. This shows that both the stability of the latent reservoir and low-level persistent viral loads are principally due to latently infected cell activation rather than ongoing active viral replication, provided that the drug efficacy is above a certain threshold value.</p>
<fig id="pcbi-1000533-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g007</object-id><label>Figure 7</label><caption>
<title>Relative contributions of ongoing viral replication and latent cell activation.</title>
<p><bold>A and B:</bold> the effects of ongoing viral replication (influenced by the overall drug efficacy) on the latent reservoir and viral load in the model given by Eq. (6). Different drug efficacies are used: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e302" xlink:type="simple"/></inline-formula> (red dashed line) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e303" xlink:type="simple"/></inline-formula> (blue solid line). Ongoing viral replication is only a minor contributor to the stability of the latent reservoir and low-level persistent viremia, as indicated by the minor effect of changing drug efficacy from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e304" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e305" xlink:type="simple"/></inline-formula>. <bold>C and D:</bold> relative contributions of ongoing viral replication (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e306" xlink:type="simple"/></inline-formula> was fixed) and latent cell activation to the latent reservoir and viral persistence. <bold>C:</bold> the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e307" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e308" xlink:type="simple"/></inline-formula>, and <bold>D:</bold> the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e309" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e310" xlink:type="simple"/></inline-formula>. We chose <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e311" xlink:type="simple"/></inline-formula>. The other parameter values used are listed in <xref ref-type="table" rid="pcbi-1000533-t001">Table 1</xref>.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g007" xlink:type="simple"/></fig>
<p>We further compare the relative contributions of ongoing viral replication and latent cell activation to the latent reservoir and viral persistence. In <xref ref-type="fig" rid="pcbi-1000533-g007">Figure 7<bold>C</bold></xref>, we plot the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e312" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e313" xlink:type="simple"/></inline-formula>, which represent the contributions to the latent cell pool coming from ongoing viral replication and the net effect of latent cell activation and return to latency, respectively. We find that the ratio is very small, indicating that the contribution of ongoing viral replication to the latent reservoir size is very small. In <xref ref-type="fig" rid="pcbi-1000533-g007">Figure 7<bold>D</bold></xref>, we plot the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e314" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e315" xlink:type="simple"/></inline-formula>, which represent the contributions to the viral load by <italic>de novo</italic> viral infection and the transition from activated latently infected cells into productively infected cells, respectively. The ratio is less than 1 except a few “blips” where latently infected cell activations occur. Thus, in the absence of activation, <italic>de novo</italic> viral infection is a minor factor contributing to the viral load, whereas viral blips are mainly due to <italic>de novo</italic> viral infection. However, we notice that the virus causing <italic>de novo</italic> viral infection is mainly released from latent cell activation (<xref ref-type="fig" rid="pcbi-1000533-g007">Figure 7<bold>C</bold></xref>). Therefore, viral persistence and the stability of the latent reservoir arise primarily from occasional activation of latently infected cells upon antigen encounter. Residual active viral replication during HAART is only a minor factor.</p>
<p>We have also performed sensitivity tests on several parameters when studying the relative contributions. The ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e316" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e317" xlink:type="simple"/></inline-formula> increases when we increase the activation rate of latently infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e318" xlink:type="simple"/></inline-formula>, or the fraction of infections that result in latency, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e319" xlink:type="simple"/></inline-formula>, or decrease the reversion rate to latency, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e320" xlink:type="simple"/></inline-formula>. In <xref ref-type="fig" rid="pcbi-1000533-g008">Figure 8</xref>, we examined the effects of different parameter values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e321" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e322" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e323" xlink:type="simple"/></inline-formula> on the ratio of relative contributions. As the activation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e324" xlink:type="simple"/></inline-formula> increases, more latently infected cells are activated, leading to more substantial replenishment of the latent reservoir and higher amplitudes of viral blips. However, even when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e325" xlink:type="simple"/></inline-formula> has a 10-fold increase (notice that in this case the transient viral load can reach above <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e326" xlink:type="simple"/></inline-formula>, which is normally not regarded as a viral blip), we observe that the ratio of the relative contributions remains almost the same (<xref ref-type="fig" rid="pcbi-1000533-g008">Figure 8<bold>A</bold></xref>). When the fraction of infections that lead to latency <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e327" xlink:type="simple"/></inline-formula> increases or the reversion rate to latency <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e328" xlink:type="simple"/></inline-formula> decreases, we observe similar effects on the viral load and the ratio of contributions (<xref ref-type="fig" rid="pcbi-1000533-g008">Figures 8<bold>B</bold> and 8<bold>C</bold></xref>). Viral load does not change much. The ratio is far less than 1 (except when viral blips occur), supporting the conclusion that the latent reservoir persistence is mainly maintained by latently infected cell activation rather than ongoing viral replication. Notice that with a very large <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e329" xlink:type="simple"/></inline-formula> or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e330" xlink:type="simple"/></inline-formula> or a very small <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e331" xlink:type="simple"/></inline-formula> we do not generate viral blips with realistic amplitude (<xref ref-type="fig" rid="pcbi-1000533-g008">Figure 8<bold>A</bold></xref>) or a slow decay of the latent reservoir (<xref ref-type="fig" rid="pcbi-1000533-g008">Figures 8<bold>B</bold> and 8<bold>C</bold></xref>).</p>
<fig id="pcbi-1000533-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g008</object-id><label>Figure 8</label><caption>
<title>Sensitivity tests on several parameters when studying the relative contributions using model (6).</title>
<p>The upper panels: the latent reservoir size; the middle panels: viral load; and the lower panels: the ratio of the relative contributions, i.e., the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e332" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e333" xlink:type="simple"/></inline-formula>. In column <bold>A</bold>, we use different activation rates: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e334" xlink:type="simple"/></inline-formula> (blue solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e335" xlink:type="simple"/></inline-formula> (red dashed), and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e336" xlink:type="simple"/></inline-formula> (purple dotted). There is no change in the ratio of relative contributions. In column <bold>B</bold>, we use different fractions of new infections that result in latency: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e337" xlink:type="simple"/></inline-formula> (blue solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e338" xlink:type="simple"/></inline-formula> (red dashed), and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e339" xlink:type="simple"/></inline-formula> (purple dotted). In column <bold>C</bold>, we use different reversion rates to latency: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e340" xlink:type="simple"/></inline-formula> (blue solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e341" xlink:type="simple"/></inline-formula> (red dashed), and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e342" xlink:type="simple"/></inline-formula> (purple dotted). The other parameter values used are the same as those in <xref ref-type="fig" rid="pcbi-1000533-g007">Figure 7</xref>.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g008" xlink:type="simple"/></fig></sec><sec id="s3d">
<title>Homeostatic proliferation of latently infected cells: another possible mechanism for the latent reservoir persistence</title>
<p>As shown in previous sections, occasional activation of latently infected cells upon antigen encounter can transiently produce a large number of activated cells, a small part of which can revert to the latent state and hence replenish the latent reservoir. In fact, several other sources might also reseed the latent cell pool and contribute to a stable latent reservoir: (1) homeostatic proliferation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e343" xlink:type="simple"/></inline-formula> memory T cells regulated through combined effects of interleukin 7 (IL-7) and T cell receptor (TCR) signaling <xref ref-type="bibr" rid="pcbi.1000533-Seddon1">[57]</xref>; (2) “bystander” proliferation of latently infected cells induced by interferons or other cytokines released during the course of immune responses that do not cause the transition from the latent to active infection <xref ref-type="bibr" rid="pcbi.1000533-Kim1">[30]</xref>; (3) latently infected cells generated during thymopoiesis (in which immature hematopoietic precursor cells mature after a series of replication, differentiation and selection steps) suggested by the SCID-hu (Thy/Liv) mouse model <xref ref-type="bibr" rid="pcbi.1000533-Brooks1">[58]</xref>; (4) latently infected cells transported from drug sanctuary sites or cells latently infected by virus released from drug sanctuary sites. A recent study by Chomont et al. <xref ref-type="bibr" rid="pcbi.1000533-Chomont1">[39]</xref> provides the first evidence supporting that the latent reservoir size and persistence can be maintained by homeostatic proliferation of latently infected cells. The proliferation of cells with provirus was also observed in another study <xref ref-type="bibr" rid="pcbi.1000533-Bull1">[59]</xref>. Motivated by these mechanisms of reservoir replenishment, we include a logistic term that represents homeostatic proliferation of latently infected cells in the basic model (see Eq. (7) in <xref ref-type="sec" rid="s2">Methods</xref>).</p>
<p>The homeostasis model can robustly describe the multiphasic viral decline following initiation of combination antiretroviral treatment, and maintain both low-level persistent viremia and the latent reservoir during therapy. <xref ref-type="fig" rid="pcbi-1000533-g009">Figure 9</xref> shows the latent reservoir size, viral load and the ratio of relative contributions to the latent reservoir persistence of ongoing viral replication to latently infected cell proliferation with different parameter values. In the first row, we let the proliferation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e344" xlink:type="simple"/></inline-formula> change but fix the total body carrying capacity of latently infected cells to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e345" xlink:type="simple"/></inline-formula> (i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e346" xlink:type="simple"/></inline-formula>). We observe that different latently infected cell proliferation rates yield different viral loads and different decay rates of the latent reservoir during the third phase. A larger <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e347" xlink:type="simple"/></inline-formula> leads to higher levels of virus and latently infected cells. Consequently, a larger <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e348" xlink:type="simple"/></inline-formula> corresponds to a slower decay or a longer half-life of the viral load and the latent reservoir during the third phase (<xref ref-type="fig" rid="pcbi-1000533-g009">Figures 9<bold>A</bold> and 9<bold>B</bold></xref>). In the second row, we show the changes in latently infected cells and viral loads with a fixed homeostatic proliferation rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e349" xlink:type="simple"/></inline-formula>. The total body carrying capacity of latently infected cells varies from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e350" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e351" xlink:type="simple"/></inline-formula> per patient (i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e352" xlink:type="simple"/></inline-formula> varies from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e353" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e354" xlink:type="simple"/></inline-formula>). The larger carrying capacity, the higher levels of residual virus and latently infected cells (<xref ref-type="fig" rid="pcbi-1000533-g009">Figures 9<bold>D</bold> and 9<bold>E</bold></xref>). It is interesting to observe that the time needed for the viral load to decline from the initial value <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e355" xlink:type="simple"/></inline-formula> to below <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e356" xlink:type="simple"/></inline-formula> is short for a small carrying capacity. For example, when the total body carrying capacity is <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e357" xlink:type="simple"/></inline-formula> (red dash-dotted line, <xref ref-type="fig" rid="pcbi-1000533-g009">Figure 9<bold>E</bold></xref>), it takes only about two weeks for the viral load to decline from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e358" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e359" xlink:type="simple"/></inline-formula>. This is not typically observed in clinical trials. The first phase of viral decay causing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e360" xlink:type="simple"/></inline-formula> viral decline usually takes about 2 weeks and the viral load will not decrease to below the limit of detection until a few months after initiation of HAART <xref ref-type="bibr" rid="pcbi.1000533-Perelson1">[4]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Hammer1">[6]</xref>. This shortcoming can be overcome by incorporating a second infected cell population — long-lived infected cells <xref ref-type="bibr" rid="pcbi.1000533-Perelson1">[4]</xref>. In fact, Perelson et al. <xref ref-type="bibr" rid="pcbi.1000533-Perelson1">[4]</xref> proposed that the loss of long-lived infected cells, such as infected macrophages with the half-life of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e361" xlink:type="simple"/></inline-formula> weeks, might be a major contributor to the second phase. In this section, for simplicity we do not include the long-lived population. We choose the total body carrying capacity to be <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e362" xlink:type="simple"/></inline-formula> (blue solid line, <xref ref-type="fig" rid="pcbi-1000533-g009">Figure 9<bold>E</bold></xref>) so that the viral load decreases to below 50 copies/mL after about three-month treatment.</p>
<fig id="pcbi-1000533-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g009</object-id><label>Figure 9</label><caption>
<title>Numerical simulations of the homeostasis model (Eq. (7)) and sensitivity tests of several parameters.</title>
<p>The system is at steady state and at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e363" xlink:type="simple"/></inline-formula> drug is applied. <bold>A, D, G</bold> and <bold>J</bold>: the latent reservoir size; <bold>B, E, H</bold> and <bold>K</bold>: viral load; <bold>C, F, I</bold> and <bold>L</bold>: the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e364" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e365" xlink:type="simple"/></inline-formula>, i.e., the relative contributions to the latent reservoir persistence from ongoing viral replication and latently infected cell proliferation. <bold>A, B</bold> and <bold>C</bold>: the carrying capacity of total latently infected cells is <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e366" xlink:type="simple"/></inline-formula>. We use different proliferation rates: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e367" xlink:type="simple"/></inline-formula> (blue solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e368" xlink:type="simple"/></inline-formula> (green dash-dotted), and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e369" xlink:type="simple"/></inline-formula> (red dashed). The black solid line represents the detection limit. <bold>D, E</bold> and <bold>F</bold>: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e370" xlink:type="simple"/></inline-formula> is fixed. Different carrying capacities of the total latently infected cells are used: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e371" xlink:type="simple"/></inline-formula> (green dashed), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e372" xlink:type="simple"/></inline-formula> (blue solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e373" xlink:type="simple"/></inline-formula> (red dash-dotted). <bold>G, H</bold> and <bold>I</bold>: we use different fractions of infections that result in latency: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e374" xlink:type="simple"/></inline-formula> (red dashed), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e375" xlink:type="simple"/></inline-formula> (blue solid), and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e376" xlink:type="simple"/></inline-formula> (black dotted). <bold>J, K</bold> and <bold>L</bold>: we use different drug efficacies: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e377" xlink:type="simple"/></inline-formula> (red dashed), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e378" xlink:type="simple"/></inline-formula> (blue solid), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e379" xlink:type="simple"/></inline-formula> (black dotted). <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e380" xlink:type="simple"/></inline-formula> and the carrying capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e381" xlink:type="simple"/></inline-formula> are fixed for the last two rows. The other parameter values used are listed in <xref ref-type="table" rid="pcbi-1000533-t001">Table 1</xref>.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g009" xlink:type="simple"/></fig>
<p>We also plot the level of latently infected cells and viral load with different <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e382" xlink:type="simple"/></inline-formula>, the fraction of new infections that result in latency (<xref ref-type="fig" rid="pcbi-1000533-g009">Figures 9<bold>G</bold> and 9<bold>H</bold></xref>), and different <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e383" xlink:type="simple"/></inline-formula>, the drug efficacy (<xref ref-type="fig" rid="pcbi-1000533-g009">Figures 9<bold>J</bold> and 9<bold>K</bold></xref>). As <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e384" xlink:type="simple"/></inline-formula> increases from 0.001 to 0.01, we do not find changes in the viral load or the latent reservoir size (<xref ref-type="fig" rid="pcbi-1000533-g009">Figures 9<bold>G</bold> and 9<bold>H</bold></xref>). With the drug efficacy varying from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e385" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e386" xlink:type="simple"/></inline-formula> (ensuring that the viral load is suppressed to below the detection limit), we observe that the treatment potency has almost no effect on the latent reservoir (<xref ref-type="fig" rid="pcbi-1000533-g009">Figure 9<bold>J</bold></xref>), although a higher drug efficacy always yields a lower viral load (<xref ref-type="fig" rid="pcbi-1000533-g009">Figure 9<bold>K</bold></xref>). In our simulations, low levels of viremia persist in patients despite very effective drug treatment. This supports the idea that viral persistence under HAART is primarily due to the activation of latently infected cells.</p>
<p>We further examine the relative contributions to the latent reservoir persistence from ongoing viral replication and latently infected cell proliferation (i.e., the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e387" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e388" xlink:type="simple"/></inline-formula>) in the last column (<xref ref-type="fig" rid="pcbi-1000533-g009">Figures 9<bold>C</bold>, 9<bold>F</bold>, 9<bold>I</bold> and 9<bold>L</bold></xref>). We plot the ratio beginning at 100 days after treatment because we are interested in the relative contributions to the latent reservoir persistence when viral load is suppressed to below the detection limit. The ratio is very small for a wide range of parameter values (<xref ref-type="fig" rid="pcbi-1000533-g009">Figures 9<bold>C</bold>, 9<bold>F</bold>, 9<bold>I</bold> and 9<bold>L</bold></xref>). This suggests that latently infected cell proliferation rather than residual viral replication is major factor contributing to the latent reservoir persistence during effective treatment.</p>
<p>The model with homeostatic proliferation of latently infected cells can also generate viral blips given intermittent bursts of activation of latently infected cells (i.e., increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e389" xlink:type="simple"/></inline-formula> randomly) upon encounter with their specific antigens. <xref ref-type="fig" rid="pcbi-1000533-g010">Figure 10</xref> delineates the transition rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e390" xlink:type="simple"/></inline-formula>, the time evolution of the latent reservoir and viral load with different proliferation rates: (<bold>A</bold>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e391" xlink:type="simple"/></inline-formula>; (<bold>B</bold>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e392" xlink:type="simple"/></inline-formula>; (<bold>C</bold>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e393" xlink:type="simple"/></inline-formula>. We use a Poisson process to model the encounter between latently infected cells and their relevant antigens. The average waiting time between two encounters is assumed to be two months. In the absence of high levels of specific antigen, the transition rate is assumed to be the base value, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e394" xlink:type="simple"/></inline-formula>. When the specific antigen is present, antigenic stimulation increases the transition rate by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e395" xlink:type="simple"/></inline-formula>. Some factors such as the antigen concentration and specificity may lead to different transition rates. Here we assume <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e396" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e397" xlink:type="simple"/></inline-formula> is the base value and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e398" xlink:type="simple"/></inline-formula> is a number chosen from a uniform distribution over the interval <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e399" xlink:type="simple"/></inline-formula>. We further assume that the duration that each activation lasts obeys a normal distribution <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e400" xlink:type="simple"/></inline-formula>. As the homeostatic proliferation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e401" xlink:type="simple"/></inline-formula> decreases from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e402" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000533-g010">Figure 10<bold>A</bold></xref>) to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e403" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000533-g010">Figure 10<bold>C</bold></xref>), the decay rate of the latent reservoir increases. This is not surprising since with decreasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e404" xlink:type="simple"/></inline-formula> there is less self-renewal of latently infected cells. At a high enough proliferation rate, homeostasis of latently infected cells is able to maintain the latent reservoir size at a very stable level (<xref ref-type="fig" rid="pcbi-1000533-g010">Figure 10<bold>A</bold></xref>).</p>
<fig id="pcbi-1000533-g010" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000533.g010</object-id><label>Figure 10</label><caption>
<title>Simulations of the homeostasis model (Eq. (7)) with occasional increases of the transition rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e405" xlink:type="simple"/></inline-formula>.</title>
<p>A Poisson process with an average waiting time of 2 months is used to model the random encounter between latently infected cells and antigens. We assume the total body carrying capacity of latently infected cells is <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e406" xlink:type="simple"/></inline-formula>. Column <bold>A:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e407" xlink:type="simple"/></inline-formula>; column <bold>B:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e408" xlink:type="simple"/></inline-formula>; column <bold>C:</bold> <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e409" xlink:type="simple"/></inline-formula>. Different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e410" xlink:type="simple"/></inline-formula> represent different potentials of latently infected cells to renew themselves, and thus lead to different decay rates of the latent reservoir. The other parameter values used are listed in <xref ref-type="table" rid="pcbi-1000533-t001">Table 1</xref>.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000533.g010" xlink:type="simple"/></fig>
<p>The frequency of viral blips is also affected by the renewal potential since viral blips come directly from activation of latently infected cells. In the case of a weak renewal potential (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e411" xlink:type="simple"/></inline-formula>, <xref ref-type="fig" rid="pcbi-1000533-g010">Figure 10<bold>C</bold></xref>), a rapid decay of the latent reservoir may not generate a viral blip <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e412" xlink:type="simple"/></inline-formula> even if there is activation occurring. Thus, with a small <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e413" xlink:type="simple"/></inline-formula>, we expect a small number of viral blips over longer periods (similar to the case of a small <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e414" xlink:type="simple"/></inline-formula> in <xref ref-type="table" rid="pcbi-1000533-t002">Table 2</xref>). This also supports the observation that there is a strong inverse correlation between the decay of the latent reservoir and the number of intermittent viremic episodes observed per year <xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>.</p>
</sec></sec><sec id="s4">
<title>Discussion</title>
<p>Although several months of HAART is usually able to reduce the viral load in HIV-infected patients successfully to below the detection limit of standard assays, 50 RNA copies/mL, a low level of virus can still be detected in plasma by more sensitive assays <xref ref-type="bibr" rid="pcbi.1000533-Dornadula1">[7]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Palmer1">[8]</xref>. Despite many years of studies, there is still no single accepted explanation for the persistence of low-level viremia. It was initially thought that antiretroviral drugs would not be capable of completely suppressing residual viral replication, particularly in those sites that have poor drug penetration <xref ref-type="bibr" rid="pcbi.1000533-Kepler1">[60]</xref>. Changes in HIV-1 proviral sequences in peripheral blood mononuclear cells (PBMCs) <xref ref-type="bibr" rid="pcbi.1000533-Zhang1">[38]</xref>, and several other lines of evidence (reviewed in <xref ref-type="bibr" rid="pcbi.1000533-Pierson1">[61]</xref>) also suggest that low-level ongoing replication exists in patients on HAART whose plasma HIV-1 RNA measurements are below the limit of detection.</p>
<p>However, even if HAART is potent enough to block all new infections of susceptible T cells, virus may still be released from a stable reservoir composed of latently infected <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e415" xlink:type="simple"/></inline-formula> T cells. Studies of children with plasma virus levels below the detection limit showed that the existent virus lacked protease inhibitor resistance mutations despite the frequent use of the protease inhibitor nelfinavir, which has a low mutational barrier to resistance <xref ref-type="bibr" rid="pcbi.1000533-Persaud1">[62]</xref>. Protease sequences resembled those of virions from latently infected <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e416" xlink:type="simple"/></inline-formula> T cells, indicating that the low-level virus might originate from the latent reservoir. Amplification of plasma viral genomes in both children and adults showed that the low-level virus does not exhibit new, HAART-selected mutations and suggested that the viremia results primarily from archival, pre-HAART virus that comes from activation of latently infected cells <xref ref-type="bibr" rid="pcbi.1000533-Hermankova1">[63]</xref>. Rebounding virus in patients after interruption of long-term potent treatment was also shown to originate from activation of latently infected cells <xref ref-type="bibr" rid="pcbi.1000533-Imamichi1">[64]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Joos1">[65]</xref>. This further supports that the low-level persistent viremia during HAART comes from the latent reservoir since this continuously produced virus is most likely to rebound when treatment is stopped. Quantitative understanding of the factors and their contributions to persistent low-level viremia would provide valuable information that potentially could allow the design of more effective treatment strategies.</p>
<p>The mechanism for the stability of the latent reservoir in the setting of HAART remains controversial. The observation that intensification of antiretroviral therapy can accelerate the decay of the latent reservoir in some patients <xref ref-type="bibr" rid="pcbi.1000533-Ramratnam2">[66]</xref> suggests that residual viral replication may replenish the latent reservoir through <italic>de novo</italic> infection of susceptible cells on HAART <xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Chun6">[56]</xref>. However, to what degree residual viral replication reseeds the latent reservoir in the setting of current HAART is still unclear. A recent study by Dinoso et al. <xref ref-type="bibr" rid="pcbi.1000533-Dinoso1">[67]</xref> showed that treatment intensification could not reduce residual HIV-1 viremia in patients on HAART. Another explanation for the latent reservoir persistence stems from the intrinsic slow turnover of long-lived resting memory <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e417" xlink:type="simple"/></inline-formula> T cells <xref ref-type="bibr" rid="pcbi.1000533-Finzi3">[21]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Siliciano1">[22]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Strain1">[36]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Siliciano2">[68]</xref>. Recent evidence that some patients do not develop drug resistance despite long periods of HAART appears to support the hypothesis that the reservoir stability comes from the intrinsic stability of latently infected cells rather than ongoing viral replication <xref ref-type="bibr" rid="pcbi.1000533-Kieffer1">[69]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Ruff1">[71]</xref>. Clearly understanding the nature of the reservoir stability is of significant importance since it is directly related to treatment strategies. If the latent reservoir is reseeded by low-level virus production due to the inability of antiretroviral therapy to completely suppress viral replication, then intensification of current regimens might help diminish the size of the reservoir. If the reservoir stability comes from the intrinsic stability of the latently infected cell population, then immune activation strategies or other means of flushing the reservoir have to be developed before virus eradication can be achieved.</p>
<p>Most well-suppressed patients with plasma HIV-1 RNA below the detection limit of 50 copies/mL demonstrate transient episodes of viremia above the limit (viral blips) <xref ref-type="bibr" rid="pcbi.1000533-Dornadula1">[7]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>. Because of non-intensive sampling, the characteristics of blips, such as the occurrence timing, frequency, duration and amplitude, are not well-known. The origin and the clinical significance of viral blips under seemingly effective antiretroviral treatment remain unclear. Viral blips may come from higher levels of virus production <xref ref-type="bibr" rid="pcbi.1000533-Havlir1">[72]</xref> due to transient reduced drug concentrations, or increased target cells secondary to opportunistic infection or vaccination <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>, <xref ref-type="bibr" rid="pcbi.1000533-Jones2">[33]</xref>, <xref ref-type="bibr" rid="pcbi.1000533-Ferguson1">[73]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Jones3">[76]</xref>. They may also result from viral release from the latent reservoir because of heightened immune activation during vaccination or illness <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Tobin1">[40]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Hermankova1">[63]</xref>. Nettles et al. <xref ref-type="bibr" rid="pcbi.1000533-Nettles1">[26]</xref> suggested viral blips could also be the result of laboratory error or statistical variation. Despite plasma HIV-1 RNA greater than the detection limit, viral blips have been reported not to be associated with virological failure <xref ref-type="bibr" rid="pcbi.1000533-Havlir1">[72]</xref>, <xref ref-type="bibr" rid="pcbi.1000533-Mira1">[77]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Sklar1">[79]</xref>. However, in some studies they have been associated with viral evolution <xref ref-type="bibr" rid="pcbi.1000533-Gnthard2">[80]</xref>, including the selection of drug resistant variants <xref ref-type="bibr" rid="pcbi.1000533-CohenStuart1">[81]</xref>–<xref ref-type="bibr" rid="pcbi.1000533-Macias1">[83]</xref>, an increased risk of clinical failure <xref ref-type="bibr" rid="pcbi.1000533-Greub1">[55]</xref>, and a slower decay of the latent reservoir <xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>. Whether there exists the evolution of drug resistance during blips seems to depend on the amplitude of blips—the study by Easterbrook et al. <xref ref-type="bibr" rid="pcbi.1000533-Easterbrook1">[82]</xref> suggested that patients with transient viremia greater than 400 copies/mL are three times more likely to experience sustained viral rebound compared with those who maintain undetectable viral load.</p>
<p>In many mathematical models, the steady state viral load is very sensitive to small changes of drug efficacy and thus they cannot robustly describe the low viral load persistence during HAART <xref ref-type="bibr" rid="pcbi.1000533-Callaway1">[28]</xref>. It is also difficult to model the stability of the latent reservoir in the setting of potent treatment unless the latent cell death rate and the transition rate from the latent to productive state are extremely small <xref ref-type="bibr" rid="pcbi.1000533-Sedaghat1">[31]</xref> or balanced by bystander proliferation <xref ref-type="bibr" rid="pcbi.1000533-Kim1">[30]</xref>. If viral blips also result from activation of latently infected cells, as suggested in <xref ref-type="bibr" rid="pcbi.1000533-Jones1">[27]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Tobin1">[40]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Hermankova1">[63]</xref>, then this activation will accelerate the decay of latently infected cells and deplete the latent reservoir quickly, contrary to what was observed in clinical studies. In an attempt to examine whether intermittent viral blips can occur without seriously depleting the latent reservoir, we developed a new mathematical model that studies the latently infected cell response when cells encounter their relevant antigens.</p>
<p>Our model can robustly maintain the stability of the latent reservoir and meanwhile generate viral blips with reasonable duration and amplitude in infected individuals in the setting of HAART. We hypothesize that latently infected cells act similar to other memory cells and experience programmed proliferation and contraction upon antigenic stimulation by their recall antigens. During the response, a portion of activated latently infected cells transition into the productive class and generate viral blips. In the meanwhile, a small fraction of activated cells revert back to the resting state, providing a potential to replenish the latent reservoir. An interesting result is that this model can reconcile the divergent estimates of the decay rate of the latent reservoir in the literature. The half-life of the reservoir decay is largely determined by the frequency and duration of antigenic stimulation and by how many times the resultant activated latently infected cells proliferate during the latent cell response. In addition, we observe that assuming activated T cells remain at a low level after the rapid contraction phase (the biphasic decay model, i.e., Eq. (6)) can maintain a low level of viremia. This suggests that latently infected cell activation solely can maintain low-level viremic persistence and produce intermittent viral blips simultaneously, with the latent reservoir occasionally replenished. Model simulations show that the levels of persistent viremia and latently infected cells are not correlated with HAART potency, which suggests that low viral load persistence and the stability of the latent reservoir need not arise from ongoing active replication during HAART.</p>
<p>The conclusion that ongoing viral replication is a minor factor contributing to viral and the latent reservoir persistence is consistent with the results of recent studies <xref ref-type="bibr" rid="pcbi.1000533-Sedaghat1">[31]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Sedaghat2">[32]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Joos1">[65]</xref>,<xref ref-type="bibr" rid="pcbi.1000533-Maldarelli1">[84]</xref>. Using an assay capable of detecting HIV-1 RNA down to 1 copy/mL <xref ref-type="bibr" rid="pcbi.1000533-Palmer1">[8]</xref>, Maldarelli et al. <xref ref-type="bibr" rid="pcbi.1000533-Maldarelli1">[84]</xref> suggested that more than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e418" xlink:type="simple"/></inline-formula> of patients on HAART had quantifiable viremias (with the median of 3.1 copies/mL) for at least two years after initiation of therapy, and that the level of persistent viremia was correlated with pretherapy viremia, or “set point”, but not with the specific treatment regimen (i.e., lopinavir/ritonavir versus nelfinavir as the protease inhibitor in HAART). These observations suggest that the persistent low-level viremia is derived from virus production by reservoirs infected prior to initiation of therapy, rather than ongoing viral replication during HAART. Bailey et al. <xref ref-type="bibr" rid="pcbi.1000533-Bailey1">[85]</xref> reported that in some patients a single, homogenous but distinct viral sequence (PPC) dominated the residual plasma virus but could not be readily found in the patient's resting <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e419" xlink:type="simple"/></inline-formula> cells in peripheral blood. With the assumption that reservoir replenishment by ongoing viral replication in the presence of the PPC would eventually lead to incorporation of the PPC into the latent reservoir, and using a simple mathematical model to constrain the maximum rate of reservoir replenishment by viral replication <xref ref-type="bibr" rid="pcbi.1000533-Sedaghat2">[32]</xref>, they suggest that ongoing viral replication during HAART is unlikely to be a major factor contributing to the stability of the latent reservoir. By characterizing rebounding virus during the structured treatment interruptions, Joos et al. <xref ref-type="bibr" rid="pcbi.1000533-Joos1">[65]</xref> argue against persistence of ongoing low-level viral replication in patients under suppressive combination therapy.</p>
<p>Motivated by the observation that latently infected cells have the potential to renew themselves when stimulated by their previously encountered antigens, a much simpler phenomenological model with homeostatic proliferation of latently infected cells was proposed to study viral persistence and HIV-1 blips. The idea that the stability of the latent reservoir can be maintained by homeostatic proliferation of latently infected cells is also supported by a very recent experimental study <xref ref-type="bibr" rid="pcbi.1000533-Chomont1">[39]</xref>. Our model is able to simulate the multiphasic viral decay in patients after initiation of HAART. In this model, the homeostatic proliferation rate of latently infected cells is a key factor determining the half-life of the latent reservoir decay. A few factors, such as the concentration of antigen and its specificity, may affect the proliferation capacity of latently infected cells. In addition, the decay of the latent reservoir is inversely correlated with the frequency or amplitude of viral blips, as has been observed in the clinical study <xref ref-type="bibr" rid="pcbi.1000533-Ramratnam1">[23]</xref>.</p>
<p>Considering that the latent reservoir consists of heterogeneous mixture of latently infected T-cell clones that respond differently to different antigens, our models can be generalized to account for the heterogeneity of latently infected cells. For example, we can extend the homeostasis model by including multiple subpopulations of latently infected cells, with each subpopulation having a different transition rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e420" xlink:type="simple"/></inline-formula> (see Eq. (7)). We expect that those subpopulations specific for frequently encountered antigens will be preferentially activated and removed from the reservoir, whereas those subpopulations that are specific for rarely encountered antigens may persist without activation or be activated slowly and dominate the latent reservoir. However, this prediction can be affected by the proliferation ability <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e421" xlink:type="simple"/></inline-formula> of each subpopulation. When we extend the model with programmed expansion and contraction by including multiple subpopulations of latently infected cells, the situation is a little different. Without assuming homeostatic proliferation of latently infected cells, depletion of one subpopulation does not imply other subpopulations will grow. The dynamics of each latently infected subpopulation depends on the proliferation ability of that subpopulation (i.e., the parameter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e422" xlink:type="simple"/></inline-formula> in Eq. (4)) and the reversion rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e423" xlink:type="simple"/></inline-formula> from the activated to latent state. Unfortunately, currently we do not have data on the heterogeneity of the latent reservoir that can be compared with these models.</p>
<p>Given that the latent reservoir has been identified as a major barrier to virus eradication with current combination therapy <xref ref-type="bibr" rid="pcbi.1000533-Chun7">[86]</xref>, elimination of this reservoir by novel therapeutic approaches is required before eradication can be achieved <xref ref-type="bibr" rid="pcbi.1000533-Richman1">[87]</xref>. Our modeling results suggest that the stability of the latent reservoir is most likely due to the intrinsic stability of resting memory <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000533.e424" xlink:type="simple"/></inline-formula> T cells and their occasional replenishment by antigenic stimulation. Thus, simply intensifying current therapy to further suppress ongoing active replication may not have much impact on the decay of the latent reservoir. Immune stimulation with activating agents has been proposed as a means to “flush” virus out of the latent reservoir. However, efforts to purge the latent reservoir with these agents have unfortunately shown only limited success. For example, although a combination of OKT3 and recombinant human IL-2 resulted in apparent T cell activation and proliferation <xref ref-type="bibr" rid="pcbi.1000533-Prins1">[88]</xref>, patients failed to achieve measurable purging of the cellular HIV reservoir. Moreover, side-effects were serious and antibodies against OKT3 developed rapidly in all patients. More importantly, if the activation of T cells in the latent reservoir also induces renewal of the latent pool as suggested by the models developed in this study, then activating agents could do more harm than good. Partial eradication of the latent reservoir will not be of significant benefit to infected individuals since theoretically a single infected cell has the potential to rekindle infection <xref ref-type="bibr" rid="pcbi.1000533-Peterson1">[89]</xref>. Therefore, a combination of activating agents with antiretroviral drugs can be useful only if they lead to a complete elimination of all the latent reservoirs.</p>
<p>Unfortunately, as viral levels are driven down, say below 1 RNA copy/mL, and latently infected cells become rare, it becomes impossible to follow the dynamics of these populations. Therefore, we must rely on mathematical models to make inferences about the end game in viral eradication. Here we have presented a set of models that agree with much of our knowledge about low-level viral persistence, the latent reservoir, and viral blips. Direct experimental tests of these models would involve the examination of the latently infected cell response when cells are activated by specific antigens. In addition, all of our models suggest that there is an inverse relationship between the decay of the latent reservoir and the frequency (or amplitude) of viral blips. Thus, more accurate and frequent data on the latent reservoir size, the number of viral blips and their amplitudes also can be used to test our models.</p>
</sec></body>
<back>
<ack>
<p>We thank Rob de Boer and Ruy Ribeiro for useful discussions on T cell proliferation, and three referees for their suggestions that improved this manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1000533-Finzi1"><label>1</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Finzi</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>R</given-names></name>
</person-group>             <year>1998</year>             <article-title>Viral dynamics in HIV-1 infection.</article-title>             <source>Cell</source>             <volume>93</volume>             <fpage>665</fpage>             <lpage>671</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Simon1"><label>2</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Simon</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>
</person-group>             <year>2003</year>             <article-title>HIV-1 dynamics in vivo: implications for therapy.</article-title>             <source>Nat Rev Microbiol</source>             <volume>1</volume>             <fpage>181</fpage>             <lpage>190</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Rong1"><label>3</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2009</year>             <article-title>Modeling HIV persistence, the latent reservoir, and viral blips.</article-title>             <source>J Theor Biol</source>             <volume>260</volume>             <fpage>308</fpage>             <lpage>331</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Perelson1"><label>4</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Essunger</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Vesanen</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Decay characteristics of HIV-1-infected compartments during combination therapy.</article-title>             <source>Nature</source>             <volume>387</volume>             <fpage>188</fpage>             <lpage>191</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Gulick1"><label>5</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gulick</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Mellors</surname><given-names>JW</given-names></name>
<name name-style="western"><surname>Havlir</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Eron</surname><given-names>JJ</given-names></name>
<name name-style="western"><surname>Gonzalez</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.</article-title>             <source>N Engl J Med</source>             <volume>337</volume>             <fpage>734</fpage>             <lpage>739</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Hammer1"><label>6</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hammer</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Squires</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Hughes</surname><given-names>MD</given-names></name>
<name name-style="western"><surname>Grimes</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Demeter</surname><given-names>LM</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.</article-title>             <source>N Engl J Med</source>             <volume>337</volume>             <fpage>725</fpage>             <lpage>733</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Dornadula1"><label>7</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dornadula</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>VanUitert</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Stern</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Livornese</surname><given-names>L</given-names><suffix>Jr</suffix></name>
<etal/></person-group>             <year>1999</year>             <article-title>Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.</article-title>             <source>JAMA</source>             <volume>282</volume>             <fpage>1627</fpage>             <lpage>1632</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Palmer1"><label>8</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Palmer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Wiegand</surname><given-names>AP</given-names></name>
<name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Bazmi</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Mican</surname><given-names>JM</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.</article-title>             <source>J Clin Microbiol</source>             <volume>41</volume>             <fpage>4531</fpage>             <lpage>4536</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Palmer2"><label>9</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Palmer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Wiegand</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Bernstein</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Hanna</surname><given-names>GJ</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>105</volume>             <fpage>3879</fpage>             <lpage>3884</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-DiMascio1"><label>10</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Di Mascio</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Dornadula</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Sullivan</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to &lt;5 copies per milliliter, with a half-life of 6 months.</article-title>             <source>J Virol</source>             <volume>77</volume>             <fpage>2271</fpage>             <lpage>2275</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Gunthard1"><label>11</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gunthard</surname><given-names>HF</given-names></name>
<name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name>
<name name-style="western"><surname>Fiscus</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>ZQ</given-names></name>
<name name-style="western"><surname>Eron</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.</article-title>             <source>J Infect Dis</source>             <volume>183</volume>             <fpage>1318</fpage>             <lpage>1327</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Smith1"><label>12</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Smith</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Wong</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Shao</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Hightower</surname><given-names>GK</given-names></name>
<name name-style="western"><surname>Mai</surname><given-names>SH</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission.</article-title>             <source>J Infect Dis</source>             <volume>196</volume>             <fpage>356</fpage>             <lpage>360</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Blankson1"><label>13</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Blankson</surname><given-names>JN</given-names></name>
<name name-style="western"><surname>Persaud</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
</person-group>             <year>2002</year>             <article-title>The challenge of viral reservoirs in HIV-1 infection.</article-title>             <source>Annu Rev Med</source>             <volume>53</volume>             <fpage>557</fpage>             <lpage>593</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Schrager1"><label>14</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Schrager</surname><given-names>LK</given-names></name>
<name name-style="western"><surname>D'Souza</surname><given-names>MP</given-names></name>
</person-group>             <year>1998</year>             <article-title>Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy.</article-title>             <source>JAMA</source>             <volume>280</volume>             <fpage>67</fpage>             <lpage>71</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chun1"><label>15</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chun</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Carruth</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Finzi</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>X</given-names></name>
<name name-style="western"><surname>DiGiuseppe</surname><given-names>JA</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.</article-title>             <source>Nature</source>             <volume>387</volume>             <fpage>183</fpage>             <lpage>188</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chun2"><label>16</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chun</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Finzi</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Margolick</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Chadwick</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Schwartz</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>1995</year>             <article-title>In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.</article-title>             <source>Nat Med</source>             <volume>1</volume>             <fpage>1284</fpage>             <lpage>1290</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chun3"><label>17</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chun</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Engel</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Mizell</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Ehler</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name>
</person-group>             <year>1998</year>             <article-title>Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines.</article-title>             <source>J Exp Med</source>             <volume>188</volume>             <fpage>83</fpage>             <lpage>91</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chun4"><label>18</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chun</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Stuyver</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Mizell</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Ehler</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Mican</surname><given-names>JA</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>94</volume>             <fpage>13193</fpage>             <lpage>13197</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Finzi2"><label>19</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Finzi</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hermankova</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pierson</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Carruth</surname><given-names>LM</given-names></name>
<name name-style="western"><surname>Buck</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.</article-title>             <source>Science</source>             <volume>278</volume>             <fpage>1295</fpage>             <lpage>1300</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Wong1"><label>20</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wong</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Hezareh</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Günthard</surname><given-names>HF</given-names></name>
<name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name>
<name name-style="western"><surname>Ignacio</surname><given-names>CC</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.</article-title>             <source>Science</source>             <volume>278</volume>             <fpage>1291</fpage>             <lpage>1295</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Finzi3"><label>21</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Finzi</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Blankson</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Margolick</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Chadwick</surname><given-names>K</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.</article-title>             <source>Nat Med</source>             <volume>5</volume>             <fpage>512</fpage>             <lpage>517</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Siliciano1"><label>22</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Siliciano</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Kajdas</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Finzi</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Quinn</surname><given-names>TC</given-names></name>
<name name-style="western"><surname>Chadwick</surname><given-names>K</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.</article-title>             <source>Nat Med</source>             <volume>9</volume>             <fpage>727</fpage>             <lpage>728</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Ramratnam1"><label>23</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ramratnam</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Mittler</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Boden</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.</article-title>             <source>Nat Med</source>             <volume>6</volume>             <fpage>82</fpage>             <lpage>85</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-DiMascio2"><label>24</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Di Mascio</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Louie</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hogan</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Viral blip dynamics during highly active antiretroviral therapy.</article-title>             <source>J Virol</source>             <volume>77</volume>             <fpage>12165</fpage>             <lpage>12172</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-DiMascio3"><label>25</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Di Mascio</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Percus</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Percus</surname><given-names>OE</given-names></name>
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Duration of an intermittent episode of viremia.</article-title>             <source>Bull Math Biol</source>             <volume>67</volume>             <fpage>885</fpage>             <lpage>900</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Nettles1"><label>26</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Nettles</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Kieffer</surname><given-names>TL</given-names></name>
<name name-style="western"><surname>Kwon</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Monie</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>Y</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.</article-title>             <source>JAMA</source>             <volume>293</volume>             <fpage>817</fpage>             <lpage>829</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Jones1"><label>27</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jones</surname><given-names>LE</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2007</year>             <article-title>Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>45</volume>             <fpage>483</fpage>             <lpage>493</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Callaway1"><label>28</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Callaway</surname><given-names>DS</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2002</year>             <article-title>HIV-1 infection and low steady state viral loads.</article-title>             <source>Bull Math Biol</source>             <volume>64</volume>             <fpage>29</fpage>             <lpage>64</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Muller1"><label>29</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Muller</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Vigueras-Gomez</surname><given-names>JF</given-names></name>
<name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>
</person-group>             <year>2002</year>             <article-title>Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection.</article-title>             <source>J Virol</source>             <volume>76</volume>             <fpage>8963</fpage>             <lpage>8965</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Kim1"><label>30</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kim</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2006</year>             <article-title>Viral and latent reservoir persistence in HIV-1-infected patients on therapy.</article-title>             <source>PLoS Comput Biol</source>             <volume>2</volume>             <fpage>e135</fpage>          </element-citation></ref>
<ref id="pcbi.1000533-Sedaghat1"><label>31</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
<name name-style="western"><surname>Wilke</surname><given-names>CO</given-names></name>
</person-group>             <year>2008</year>             <article-title>Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.</article-title>             <source>BMC Infect Dis</source>             <volume>8</volume>             <fpage>2</fpage>          </element-citation></ref>
<ref id="pcbi.1000533-Sedaghat2"><label>32</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Brennan</surname><given-names>TP</given-names></name>
<name name-style="western"><surname>Wilke</surname><given-names>CO</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
</person-group>             <year>2007</year>             <article-title>Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.</article-title>             <source>PLoS Pathog</source>             <volume>3</volume>             <fpage>e122</fpage>          </element-citation></ref>
<ref id="pcbi.1000533-Jones2"><label>33</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jones</surname><given-names>LE</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2005</year>             <article-title>Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.</article-title>             <source>Bull Math Biol</source>             <volume>67</volume>             <fpage>1227</fpage>             <lpage>1251</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Rong2"><label>34</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2009</year>             <article-title>Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips.</article-title>             <source>Math Biosci</source>             <volume>217</volume>             <fpage>77</fpage>             <lpage>87</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chun5"><label>35</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chun</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Justement</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Moir</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Hallahan</surname><given-names>CW</given-names></name>
<name name-style="western"><surname>Maenza</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.</article-title>             <source>J Infect Dis</source>             <volume>195</volume>             <fpage>1762</fpage>             <lpage>1764</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Strain1"><label>36</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Strain</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Gunthard</surname><given-names>HF</given-names></name>
<name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name>
<name name-style="western"><surname>Ignacio</surname><given-names>CC</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>DM</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>100</volume>             <fpage>4819</fpage>             <lpage>4824</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Strain2"><label>37</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Strain</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Little</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Daar</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name>
<name name-style="western"><surname>Gunthard</surname><given-names>HF</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.</article-title>             <source>J Infect Dis</source>             <volume>191</volume>             <fpage>1410</fpage>             <lpage>1418</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Zhang1"><label>38</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Ramratnam</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Tenner-Racz</surname><given-names>K</given-names></name>
<name name-style="western"><surname>He</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Vesanen</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.</article-title>             <source>N Engl J Med</source>             <volume>340</volume>             <fpage>1605</fpage>             <lpage>1613</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chomont1"><label>39</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chomont</surname><given-names>N</given-names></name>
<name name-style="western"><surname>El-Far</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Ancuta</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Trautmann</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Procopio</surname><given-names>FA</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferaiton.</article-title>             <source>Nat Med</source>             <volume>15</volume>             <fpage>893</fpage>             <lpage>900</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Tobin1"><label>40</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tobin</surname><given-names>NH</given-names></name>
<name name-style="western"><surname>Learn</surname><given-names>GH</given-names></name>
<name name-style="western"><surname>Holte</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Melvin</surname><given-names>AJ</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.</article-title>             <source>J Virol</source>             <volume>79</volume>             <fpage>9625</fpage>             <lpage>9634</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Homann1"><label>41</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Homann</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Teyton</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Oldstone</surname><given-names>MB</given-names></name>
</person-group>             <year>2001</year>             <article-title>Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory.</article-title>             <source>Nat Med</source>             <volume>7</volume>             <fpage>913</fpage>             <lpage>919</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Pamer1"><label>42</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pamer</surname><given-names>EG</given-names></name>
</person-group>             <year>2004</year>             <article-title>Immune responses to Listeria monocytogenes.</article-title>             <source>Nat Rev Immunol</source>             <volume>4</volume>             <fpage>812</fpage>             <lpage>823</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Ahmed1"><label>43</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Gray</surname><given-names>D</given-names></name>
</person-group>             <year>1996</year>             <article-title>Immunological memory and protective immunity: understanding their relation.</article-title>             <source>Science</source>             <volume>272</volume>             <fpage>54</fpage>             <lpage>60</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-DeBoer1"><label>44</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>De Boer</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Oprea</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Antia</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Murali-Krishna</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>Recruitment times, proliferation, and apoptosis rates during the CD8(+) T-cell response to lymphocytic choriomeningitis virus.</article-title>             <source>J Virol</source>             <volume>75</volume>             <fpage>10663</fpage>             <lpage>10669</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-DeBoer2"><label>45</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>De Boer</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Homann</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2003</year>             <article-title>Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection.</article-title>             <source>J Immunol</source>             <volume>171</volume>             <fpage>3928</fpage>             <lpage>3935</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Holte1"><label>46</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Holte</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Melvin</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Mullins</surname><given-names>JI</given-names></name>
<name name-style="western"><surname>Tobin</surname><given-names>NH</given-names></name>
<name name-style="western"><surname>Frenkel</surname><given-names>LM</given-names></name>
</person-group>             <year>2006</year>             <article-title>Density-dependent decay in HIV-1 dynamics.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>41</volume>             <fpage>266</fpage>             <lpage>276</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Kaech1"><label>47</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kaech</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Wherry</surname><given-names>EJ</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name>
</person-group>             <year>2002</year>             <article-title>Effector and memory T-cell differentiation: implications for vaccine development.</article-title>             <source>Nat Rev Immunol</source>             <volume>2</volume>             <fpage>251</fpage>             <lpage>262</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Hockett1"><label>48</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hockett</surname><given-names>RD</given-names></name>
<name name-style="western"><surname>Kilby</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Derdeyn</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Saag</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Sillers</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.</article-title>             <source>J Exp Med</source>             <volume>189</volume>             <fpage>1545</fpage>             <lpage>1554</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chen1"><label>49</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>HY</given-names></name>
<name name-style="western"><surname>Di Mascio</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>
</person-group>             <year>2007</year>             <article-title>Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>104</volume>             <fpage>19079</fpage>             <lpage>19084</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Perelson2"><label>50</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Kirschner</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>De Boer</surname><given-names>R</given-names></name>
</person-group>             <year>1993</year>             <article-title>Dynamics of HIV infection of <italic>CD</italic>4<sup>+</sup> T cells.</article-title>             <source>Math Biosci</source>             <volume>114</volume>             <fpage>81</fpage>             <lpage>125</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Iezzi1"><label>51</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Iezzi</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Karjalainen</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></name>
</person-group>             <year>1998</year>             <article-title>The duration of antigenic stimulation determines the fate of naive and effector T cells.</article-title>             <source>Immunity</source>             <volume>8</volume>             <fpage>89</fpage>             <lpage>95</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-JelleyGibbs1"><label>52</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jelley-Gibbs</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Lepak</surname><given-names>NM</given-names></name>
<name name-style="western"><surname>Yen</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Swain</surname><given-names>SL</given-names></name>
</person-group>             <year>2000</year>             <article-title>Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation.</article-title>             <source>J Immunol</source>             <volume>165</volume>             <fpage>5017</fpage>             <lpage>5026</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Kaech2"><label>53</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kaech</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name>
</person-group>             <year>2001</year>             <article-title>Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells.</article-title>             <source>Nat Immunol</source>             <volume>2</volume>             <fpage>415</fpage>             <lpage>422</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Kundig1"><label>54</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kundig</surname><given-names>TM</given-names></name>
<name name-style="western"><surname>Shahinian</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kawai</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Mittrucker</surname><given-names>HW</given-names></name>
<name name-style="western"><surname>Sebzda</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>1996</year>             <article-title>Duration of TCR stimulation determines costimulatory requirement of T cells.</article-title>             <source>Immunity</source>             <volume>5</volume>             <fpage>41</fpage>             <lpage>52</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Greub1"><label>55</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Greub</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ledergerber</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Staszewski</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Perrin</surname><given-names>L</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.</article-title>             <source>AIDS</source>             <volume>16</volume>             <fpage>1967</fpage>             <lpage>1969</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chun6"><label>56</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chun</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Nickle</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Justement</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Large</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Semerjian</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.</article-title>             <source>J Clin Invest</source>             <volume>115</volume>             <fpage>3250</fpage>             <lpage>3255</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Seddon1"><label>57</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Seddon</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Tomlinson</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Zamoyska</surname><given-names>R</given-names></name>
</person-group>             <year>2003</year>             <article-title>Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells.</article-title>             <source>Nat Immunol</source>             <volume>4</volume>             <fpage>680</fpage>             <lpage>686</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Brooks1"><label>58</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Brooks</surname><given-names>DG</given-names></name>
<name name-style="western"><surname>Kitchen</surname><given-names>SG</given-names></name>
<name name-style="western"><surname>Kitchen</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>Scripture-Adams</surname><given-names>DD</given-names></name>
<name name-style="western"><surname>Zack</surname><given-names>JA</given-names></name>
</person-group>             <year>2001</year>             <article-title>Generation of HIV latency during thymopoiesis.</article-title>             <source>Nat Med</source>             <volume>7</volume>             <fpage>459</fpage>             <lpage>464</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Bull1"><label>59</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bull</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Learn</surname><given-names>GH</given-names></name>
<name name-style="western"><surname>McElhone</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Hitti</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Lockhart</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus.</article-title>             <source>J Virol</source>             <volume>83</volume>             <fpage>6020</fpage>             <lpage>6028</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Kepler1"><label>60</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kepler</surname><given-names>TB</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>1998</year>             <article-title>Drug concentration heterogeneity facilitates the evolution of drug resistance.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>95</volume>             <fpage>11514</fpage>             <lpage>11519</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Pierson1"><label>61</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pierson</surname><given-names>T</given-names></name>
<name name-style="western"><surname>McArthur</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
</person-group>             <year>2000</year>             <article-title>Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.</article-title>             <source>Annu Rev Immunol</source>             <volume>18</volume>             <fpage>665</fpage>             <lpage>708</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Persaud1"><label>62</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Persaud</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Siberry</surname><given-names>GK</given-names></name>
<name name-style="western"><surname>Ahonkhai</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kajdas</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Monie</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.</article-title>             <source>J Virol</source>             <volume>78</volume>             <fpage>968</fpage>             <lpage>979</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Hermankova1"><label>63</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hermankova</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Ray</surname><given-names>SC</given-names></name>
<name name-style="western"><surname>Ruff</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Powell-Davis</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Ingersoll</surname><given-names>R</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>HIV-1 drug resistance profiles inchildren and adults with viral load of &lt;50 copies/ml receiving combination therapy.</article-title>             <source>JAMA</source>             <volume>286</volume>             <fpage>196</fpage>             <lpage>207</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Imamichi1"><label>64</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Imamichi</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Crandall</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Natarajan</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>MK</given-names></name>
<name name-style="western"><surname>Dewar</surname><given-names>RL</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.</article-title>             <source>J Infect Dis</source>             <volume>183</volume>             <fpage>36</fpage>             <lpage>50</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Joos1"><label>65</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Joos</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Fischer</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kuster</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Pillai</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Wong</surname><given-names>JK</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>HIV rebounds from latently infected cells, rather than from continuing low-level replication.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>105</volume>             <fpage>16725</fpage>             <lpage>16730</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Ramratnam2"><label>66</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ramratnam</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Ribeiro</surname><given-names>R</given-names></name>
<name name-style="western"><surname>He</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Chung</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Simon</surname><given-names>V</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>35</volume>             <fpage>33</fpage>             <lpage>37</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Dinoso1"><label>67</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dinoso</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name>
<name name-style="western"><surname>Wiegand</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Palmer</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Gange</surname><given-names>SJ</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>106</volume>             <fpage>9403</fpage>             <lpage>9408</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Siliciano2"><label>68</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Siliciano</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
</person-group>             <year>2004</year>             <article-title>A long-term latent reservoir for HIV-1: discovery and clinical implications.</article-title>             <source>J Antimicrob Chemother</source>             <volume>54</volume>             <fpage>6</fpage>             <lpage>9</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Kieffer1"><label>69</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kieffer</surname><given-names>TL</given-names></name>
<name name-style="western"><surname>Finucane</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Nettles</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Quinn</surname><given-names>TC</given-names></name>
<name name-style="western"><surname>Broman</surname><given-names>KW</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.</article-title>             <source>J Infect Dis</source>             <volume>189</volume>             <fpage>1452</fpage>             <lpage>1465</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Monie1"><label>70</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Monie</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Simmons</surname><given-names>RP</given-names></name>
<name name-style="western"><surname>Nettles</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Kieffer</surname><given-names>TL</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.</article-title>             <source>J Virol</source>             <volume>79</volume>             <fpage>5185</fpage>             <lpage>5202</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Ruff1"><label>71</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ruff</surname><given-names>CT</given-names></name>
<name name-style="western"><surname>Ray</surname><given-names>SC</given-names></name>
<name name-style="western"><surname>Kwon</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Zinn</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Pendleton</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.</article-title>             <source>J Virol</source>             <volume>76</volume>             <fpage>9481</fpage>             <lpage>9492</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Havlir1"><label>72</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name>
<name name-style="western"><surname>Bassett</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Levitan</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Gilbert</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Tebas</surname><given-names>P</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>Prevalence and predictive value of intermittent viremia with combination hiv therapy.</article-title>             <source>JAMA</source>             <volume>286</volume>             <fpage>171</fpage>             <lpage>179</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Ferguson1"><label>73</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ferguson</surname><given-names>NM</given-names></name>
<name name-style="western"><surname>deWolf</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Ghani</surname><given-names>AC</given-names></name>
<name name-style="western"><surname>Fraser</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Donnelly</surname><given-names>CA</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>96</volume>             <fpage>15167</fpage>             <lpage>15172</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Fraser1"><label>74</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Fraser</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Ferguson</surname><given-names>NM</given-names></name>
<name name-style="western"><surname>de Wolf</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Anderson</surname><given-names>RM</given-names></name>
</person-group>             <year>2001</year>             <article-title>The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications.</article-title>             <source>Proc Biol Sci</source>             <volume>268</volume>             <fpage>2085</fpage>             <lpage>2095</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Gnthard1"><label>75</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Günthard</surname><given-names>HF</given-names></name>
<name name-style="western"><surname>Wong</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Spina</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Ignacio</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Kwok</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.</article-title>             <source>J Infect Dis</source>             <volume>181</volume>             <fpage>522</fpage>             <lpage>531</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Jones3"><label>76</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jones</surname><given-names>LE</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
</person-group>             <year>2002</year>             <article-title>Modeling the effects of vaccination on chronically infected HIV-positive patients.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>31</volume>             <fpage>369</fpage>             <lpage>377</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Mira1"><label>77</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Mira</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Macias</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Nogales</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Fernandez-Rivera</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Garcia-Garcia</surname><given-names>JA</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure.</article-title>             <source>Antivir Ther</source>             <volume>7</volume>             <fpage>251</fpage>             <lpage>256</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Raboud1"><label>78</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Raboud</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Rae</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Woods</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Harris</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Montaner</surname><given-names>JS</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients.</article-title>             <source>AIDS</source>             <volume>16</volume>             <fpage>1627</fpage>             <lpage>1632</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Sklar1"><label>79</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sklar</surname><given-names>PA</given-names></name>
<name name-style="western"><surname>Ward</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Baker</surname><given-names>RK</given-names></name>
<name name-style="western"><surname>Wood</surname><given-names>KC</given-names></name>
<name name-style="western"><surname>Gafoor</surname><given-names>Z</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Prevalence and clinical correlates of HIV viremia (‘blips’) in patients with previous suppression below the limits of quantification.</article-title>             <source>AIDS</source>             <volume>16</volume>             <fpage>2035</fpage>             <lpage>2041</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Gnthard2"><label>80</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Günthard</surname><given-names>HF</given-names></name>
<name name-style="western"><surname>Frost</surname><given-names>SD</given-names></name>
<name name-style="western"><surname>Leigh-Brown</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Ignacio</surname><given-names>CC</given-names></name>
<name name-style="western"><surname>Kee</surname><given-names>K</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.</article-title>             <source>J Virol</source>             <volume>73</volume>             <fpage>9404</fpage>             <lpage>9412</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-CohenStuart1"><label>81</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cohen Stuart</surname><given-names>JW</given-names></name>
<name name-style="western"><surname>Wensing</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Kovacs</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Righart</surname><given-names>M</given-names></name>
<name name-style="western"><surname>de Jong</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>28</volume>             <fpage>105</fpage>             <lpage>113</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Easterbrook1"><label>82</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Easterbrook</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Ives</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Waters</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Mullen</surname><given-names>J</given-names></name>
<name name-style="western"><surname>O'Shea</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to &lt;400 copies/ml.</article-title>             <source>AIDS</source>             <volume>16</volume>             <fpage>1521</fpage>             <lpage>1527</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Macias1"><label>83</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Macias</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Palomares</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Mira</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Torres</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Garcia-Garcia</surname><given-names>JA</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.</article-title>             <source>J Infect</source>             <volume>51</volume>             <fpage>195</fpage>             <lpage>200</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Maldarelli1"><label>84</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Palmer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>King</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Wiegand</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Polis</surname><given-names>MA</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.</article-title>             <source>PLoS Pathog</source>             <volume>3</volume>             <fpage>e46</fpage>          </element-citation></ref>
<ref id="pcbi.1000533-Bailey1"><label>85</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bailey</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Kieffer</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Brennan</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>PK</given-names></name>
<etal/></person-group>             <year>2006</year>             <article-title>Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.</article-title>             <source>J Virol</source>             <volume>80</volume>             <fpage>6441</fpage>             <lpage>6457</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Chun7"><label>86</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chun</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name>
</person-group>             <year>1999</year>             <article-title>Latent reservoirs of HIV: Obstacles to the eradication of virus.</article-title>             <source>Proc Natl Acad Sci USA</source>             <volume>96</volume>             <fpage>10958</fpage>             <lpage>10961</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Richman1"><label>87</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Richman</surname><given-names>DD</given-names></name>
<name name-style="western"><surname>Margolis</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Delaney</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Greene</surname><given-names>WC</given-names></name>
<name name-style="western"><surname>Hazuda</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>The challenge of finding a cure for HIV infection.</article-title>             <source>Science</source>             <volume>323</volume>             <fpage>1304</fpage>             <lpage>1307</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Prins1"><label>88</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Prins</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Jurriaans</surname><given-names>S</given-names></name>
<name name-style="western"><surname>van Praag</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Blaak</surname><given-names>H</given-names></name>
<name name-style="western"><surname>van Rij</surname><given-names>R</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.</article-title>             <source>AIDS</source>             <volume>13</volume>             <fpage>2405</fpage>             <lpage>2410</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Peterson1"><label>89</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Peterson</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Reid</surname><given-names>AP</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name>
</person-group>             <year>2007</year>             <article-title>Treatment implications of the latent reservoir for HIV-1.</article-title>             <source>Adv Pharmacol</source>             <volume>55</volume>             <fpage>411</fpage>             <lpage>425</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Mohri1"><label>90</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Mohri</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Monard</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name>
</person-group>             <year>1998</year>             <article-title>Rapid turnover of T lymphocytes in SIV-infected rhesus macaques.</article-title>             <source>Science</source>             <volume>279</volume>             <fpage>1223</fpage>             <lpage>1227</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Markowitz1"><label>91</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Louie</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Di Mascio</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.</article-title>             <source>J Virol</source>             <volume>77</volume>             <fpage>5037</fpage>             <lpage>5038</lpage>          </element-citation></ref>
<ref id="pcbi.1000533-Ramratnam3"><label>92</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ramratnam</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Binley</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.</article-title>             <source>Lancet</source>             <volume>354</volume>             <fpage>1782</fpage>             <lpage>1785</lpage>          </element-citation></ref>
</ref-list>

</back>
</article>